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Abstract 
Given the prevalence of cardiovascular disorders and the distinct lack of significant repair 
mechanisms within cardiovascular systems, effective therapy for long-term treatment of 
cardiovascular degeneration remains a significant challenge. Further, the fundamental importance 
of such systems to all mammalian life begs the development of realistic component structures for 
in vitro assessment.  
Significant effort was expended to create in vitro models, which mimicked a subset of structure 
and function of coordinate native components within cardiovascular systems. Towards this end, we 
developed a 3D-Artificial Heart Muscle (AHM) model utilizing fibrin gel and neonatal cardiac 
myocytes. We extracted functional metrics in order to probe the optimal protocol for generation of 
the tissue model. Building on the outcome of this experiment, we applied the optimal 3D-AHM 
model to a decellularized adult rat heart in order to re-append function to a complex acellular 
scaffold. The resultant bioartifical heart (BAH) model was assessed to identify the efficacy of 3D-
AHM as a functional delivery mechanism and to lay a framework for heart model development. 
An alternative strategy for the generation of 3D heart muscle was explored through magnetic 
levitation of cardiovascular cells. Magnetic sensitivity was appended to cells through incubation 
with ferromagnetic nanoparticles. The cells were then levitated and cultured within a magnetic field 
to form 3D multicellular aggregates. (MCAs) We utilized a magnetized fibrin gel scaffold in order 
to apply non-contact, magnetic stretch conditioning to our AHM model through a novel bioreactor 
system.  
 We were able to develop a highly functional 3D-AHM and extracted 4M cells as the optimal 
concentration for the generation of our artificial heart muscle. Application of a layer of 3D-AHM 
to an acellular rat heart proved the 3D-AHM an effective mechanism for delivery of a subset of 
function to a structure. Magnetic levitation generated hundreds of cell-dense, functional and 
phenotypically relevant heart muscle analogs. We have developed a completely novel system for 
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the application of mechanical stretch conditioning to artificial heart muscle models and are working 
to implement more complex conditioning systems. The work presented herein surveys the 
generation of 3 unique cardiovascular model systems and a novel method for model conditioning.  
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Chapter 1: Introduction 
Cardiovascular Disease and Tissue Engineering 
1.1 Background 
 The heart is a fairly ubiquitous organ within the animal kingdom. Though the structure may 
vary, the base action remains unchanged. While it is difficult and perhaps arbitrary to rank 
importance of common organ systems, it can be said with some degree of certainty that 
cardiovascular disorders are the most prevalent source of fatality when compared with diseases of 
other common systems such as neural, digestive, immune, etc. Humans are no exception to this 
observation as heart disease is the leading cause of death in the western world and accounts for 
roughly ¼ of the deaths in the United States annually (Go et al., 2013). More than this, treatment 
is a prolonged and expensive ordeal with a $108.9 billion annual cost in the United States alone. 
The prevalence, cost and severity of cardiovascular disorders prompts several basic questions.  
 Why are cardiovascular disorders, in particular, so pervasive and deadly? The heart, 
unlike many other common structures, lacks a significant capacity for repair. In humans, a typical 
myocardial infarction accounts for cell death on the order of a billion cells. There is no mechanism 
to replace these lost cells to anywhere near the previous numbers. By its very nature, heart disease 
is progressive. Once functional cells in the cardiovascular system are lost, the system can stabilize 
and compensate but cannot return to a fully functional state. Deleterious effects compound leading 
to further damage and destabilization of the system (Maton and Prentice-Hall 1994; Kelly et al., 
2010; Mendis et al., 2011; Finegold, Asaria, and Francis 2013). 
 What are the current treatments options? Angiotensin-converting enzyme (ACE) 
inhibitors, angiotensin II receptor blockers, digoxin, statins, aspirin and beta blockers are a few of 
the medications used to treat cardiovascular disease (Hennekens, Dyken, and Fuster 1997; 
Gutierrez et al., 2012; Singh, Shishehbor, and Ansell 2007). Pharmacological treatments for heart 
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disease certainly have benefit, but cannot address a fundamental lack of sufficient healthy tissue. 
Small molecules are limited in their activity by the lack of an innate repair mechanism. Primary 
methods of action typically encourage peripheral compensation, or mitigate side effects of 
overcompensation by the heart itself. Counterpulsation devices (CPDs), intra-aortic balloon pumps 
(IABPs), left ventricular assist devices (LVADs) and total artificial hearts (TAHs) are a few 
examples of medical devices designed to combat heart disease (J. Wei et al., 1998; Kantrowitz et 
al., 1968; Scheidt et al., 1982; McCarthy et al., 1995). Immunogenic and thrombogenic responses 
of the host to such devices limit the scope of their application. Such devices are typically seen only 
as a bridge to transplant and not as a final solution. The only true long term therapy for end-stage 
heart failure is heart transplant. Only 3,000 heart transplants are performed in the U.S. every year 
leaving some 30,000-70,000 Americans without proper treatment. A lack of compatible organs 
severely limits the only long-term therapy for the most deadly condition known to man (Go et al. 
2014). 
What is the way forward? While the current state of therapy for heart disease remains 
insufficient, there is promising research that indicates two new treatment paths are evolving. One 
such path centers on stemming the progression of heart disease. By attempting to address the lack 
of a repair mechanism, researchers hope to replace damaged cells with new and healthy tissue. It 
is hoped that protocols for either guided injection of healthy cells, or application of tissue 
engineered heart muscle to damaged areas of the heart, may sufficiently compensate for the 
functional loss experienced during cardiac trauma. Another far more ambitious goal is to find a 
new source for organ transplant. There have been many promising advances which indicate that it 
may one day be possible to grow a patient specific heart replacement outside of the body. 
1.2 Tissue Engineering 
Tissue engineering strategies are focused on the fabrication of artificial tissue constructs in 
a controlled laboratory environment (Atala 2004; Fisher and Mauck 2013; Hecker and Birla 2007; 
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Luda Khait et al., 2008; Nerem 2006; Rustad et al., 2010; Sipe 2002). The definition of tissue 
engineering was provided by Dr. Robert Langer in one of his seminal papers, where he states that 
“Tissue engineering is an interdisciplinary field that applies the principles of engineering and the 
life sciences toward the development of biological substitutes that restore, maintain, or improve 
tissue function” (Langer and Joseph 1993). This seminal publication has been influential in the 
field and has resulted in an exponential increase in research participation. Advances in tissue and 
organ fabrication technology have led to clinical implantation of bioengineered tracheas and 
bladders and organ model have been developed for artificial hearts, lungs and kidneys.  
Tissue Engineering represents a relatively new approach to address existing medical 
conditions. Translation of cardiovascular tissue engineering strategies into the clinic may allow 
therapy to stem the progression of cardiovascular disorders and eventually provide a source for new 
donor organs. Along these lines, researchers have attempted to recreate many functional 
components of the cardiovascular system, including heart muscle, valves, SA and AV nodes, blood 
vessels, ventricles, atriums and indeed entire hearts. 
The field of cardiovascular tissue engineering has rapidly expanded since the first 
publication in 1997 (Chiu et al., 2011; Williams et al., 2014; Tallawi et al., 2014; Bhaarathy et al., 
2014; Baheiraei et al., 2014; Shevach et al., 2014; Dhingra, Weisel, and Li 2014; Ehler and 
Jayasinghe 2014; Cui et al. 2014; Qazi et al., 2014; Yu et al., 2014; Matsuura, Masuda, and Shimizu 
2014; Srinivasa Reddy et al., 2014; Annabi et al., 2013; Fleischer et al., 2013; Ravichandran et al., 
2013; Gálvez-Montón et al., 2013; Prabhakaran et al., 2012; Ye, Sullivan, and Black 2011; 
Prabhakaran et al., 2011; Curtis and Russell 2009; Blan and Birla 2008; H.-J. Wei et al., 2006; Dar 
et al., 2002; Shimizu, Yamato, Isoi, et al., 2002; Shimizu, Yamato, Akutsu, et al., 2002; Shimizu et 
al., 2001; Papadaki et al., 2001; Li et al., 2000; Leor et al., 2000; W. H. Zimmermann et al., 2000; 
Li et al., 1999; Akins et al., 1999; Eschenhagen et al., 1997). The most common strategy to fabricate 
3D-AHM has been to culture neonatal cardiac myocytes within a suitable 3D scaffold, resulting in 
artificial tissue that replicates a partial subset of mammalian heart muscle function (Y. Huang, 
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Khait, and Birla 2007; Baar et al., 2005; Bursac et al., 1999; Curtis and Russell 2009; Blan and 
Birla 2008; Dar et al., 2002; Li et al., 1999; W. H. Zimmermann et al., 2000; Akins et al., 1999; 
Papadaki et al., 2001; Li et al., 2000). Three pillars of heart muscle tissue engineering have evolved: 
cells, biomaterials and bioreactors. 
 Cells – cells provide the functional component of 3D artificial tissue and most models of 
artificial heart muscle have been developed using neonatal cardiac myocytes. While 
artificial tissue fabricated using neonatal cells cannot be used clinically, these models 
provide valuable insight into 3D organization and development.    
 Biomaterials – many biomaterials have been tested to support artificial heart muscle, 
including fibrin, collagen, alginate, chitosan and polyglycolic acid. These materials have 
demonstrated varying degrees of success and replicated partial functionality of artificial 
heart muscle.      
 Bioreactors – bioreactors are used to replicate in vivo conditions during controlled in vitro 
culture; specific signals include mechanical stretch, electrical stimulation and fluid stress. 
These signals are important in guiding the formation and function.   
 
 
Figure 1:  Tissue Engineering Process, A general outline of the process for developing a 
                  bioengineered tissue model through tissue engineering. 
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1.3 Key Challenges 
The vast potential of the field of tissue engineering presents clear and astounding goals to 
those researchers who endeavor to bioengineer tissues. It is clear much benefit could be provided 
through a successful development of nearly any engineered organ system. While there have been 
promising advances and even intermediate developments with clinical applications, many issues 
separate the immediate future of tissue engineering from the stuff of science fiction. 
1.3.1 Cell Sourcing 
A primary concern when attempting to replicate an organ, system or tissue, is where do 
you get your cells? There are a multitude of issues surrounding the selection of an appropriate cell 
source. This question transcends concerns of science into the murky realm of morality. Embryonic 
stem cells were long considered the future of a multitude of therapeutic scientific endeavors, and 
tissue engineering was no exception. The ability of embryonic stem cells to mature into nearly any 
phenotype, given the proper conditioning, made them the center of study in many countries for 
several years. Moral concerns extended from the source of these cells. It is perhaps not hard to 
envision a dystopian future where embryos are cultured in vats and harvested for their cells. In 
2006, Yamanaka’s group uncovered a Nobel Prize winning method to induce mature adult cells to 
a pluripotent state (Takahashi and Yamanaka 2006). Adult cells can now be reprogrammed to return 
to a state where they are roughly as phenotypically plastic as embryonic stem cells, alleviating 
much societal pressure on the field. There is little inherent moral dilemma when cells can be 
harvested from consenting adults. Still, there are many issues with this method as well. The genes 
which were inserted into the cells to induce pluripotency are inherently oncogenic. While biological 
techniques have evolved to completely remove these oncogenic sequences post cellular 
transformation, the yield of such techniques is still fairly low. Further, successful differentiation of 
iPS cells to specific cell types remains a significant challenge. While protocols have been 
developed, the efficiency of directed differentiation of iPS cells leaves much to be desired. Given 
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the vast numbers of cells expected to be required in even the simplest tissue engineered models, a 
more efficient means of transformation and differentiation is necessary. 
As such, many models rely heavily on neonatal, mesenchymal, stromal and other readily 
available and well understood cell types in order to generate tissue models. Clinically, a well 
understood, readily available and patient specific cell source is ideal. Autologous cell sourcing can 
eliminate any immune response, and functional integration of created constructs into host tissue 
will eliminate thrombogenic and external control considerations (Foy 2007). 
1.3.2 Natural vs. Synthetic Scaffolds 
A debate regarding the future of biomaterials within and outside the field of tissue 
engineering has arisen due to arguments over the proper choice for scaffold material. Natural 
scaffolds offer much in the way of mimicking properties which may be found in the 
microenvironments of cells in natural tissue. Cellular binding sites, microarchitecture and 
composition of natural scaffolds are generally considered to be more sophisticated than those of 
synthetic scaffold mimics. Synthetic scaffolds however, can be controlled via their manufacturing 
process. Favorable results will be more readily reproducible using synthetic scaffolds as the 
synthesis process will be the same every time. Further, synthetic scaffolds offer an off the shelf 
option. Finally, FDA approval of synthetic materials is a far less complex and time consuming 
process. While natural scaffolds currently offer the best properties for replication of bodily tissue 
features, I believe that advancements within the field of synthetics will inevitably lead to a shift 
towards controlled synthesis biomaterials. 
1.3.3 Microenvironment and cellular distribution  
 Throughout the history of cellular biology, it has become clear that cellular function and 
activity rely heavily on signals from the environment around the cell. Cell-cell communication, 
ECM protein signal cascades and small molecule uptake are just a few ways with which the cell 
can communicate with its environment. The context in which a cell is placed plays a pivotal role in 
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the cell’s action. As such, it is important to mimic the cellular composition and organization of 
native tissues at the most granular level of detail in order to achieve the optimal cellular phenotype. 
Further, tissues are often aligned in complex fashion with distinct layers of differing cell types. 
Replicating these patterns is not straightforward and guided cellularization of biomaterials has 
become a popular area of study.  
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Chapter 2: Artificial Heart Muscle Model 
Optimizing a spontaneously contracting heart tissue patch with rat 
neonatal cardiac cells on fibrin gel 
Over the years, engineered cardiac tissues have been constructed with primary or stem 
cell-derived cardiac cells on natural or synthetic scaffolds. They represent a tremendous 
potential for treatment of injured areas or repair of congenital heart defects through addition 
of tensional support and delivery of sufficient cells. In this study 1 to 6 million (M) neonatal 
cardiac cells were seeded on fibrin gels to fabricate cardiac tissue patches. We analyzed the 
effects of culture time and cell density on spontaneous contraction rates, twitch forces, 
electrocardiograms and expression of connexin 43. The patches were also electrically paced at 
various frequencies to determine the response in contraction rate. Patches of all cell densities 
exhibited maximum contraction rates between 305-410 bpm within the first 4 days after 
plating. When measuring contractile twitch forces, low cell density (1-3M) patches sustained 
a longer rhythmic contraction whereas high cell density patches just an arrhythmic contraction. 
1-6M patches generated 2245-8514 kN/m3 of the high rate mean and 3959-14065 kN/m3 of 
the low rate mean contractile forces on days 4-6. After patch formation, both high and low rate 
contractile forces and electrical pacing response frequency dramatically decreased with culture 
period. The difference in maximum contraction rates with 1-6M resulted from the density-
related variation of pacemaker cells which competitively paced within the tissue; the greater 
twitch forces generated by higher cell density relied on a thicker real cardiac layer which also 
summed greater R wave amplitude. Overpopulation of myoblasts and the aging and apoptosis 
of cardiomyocytes might be responsible for the decreases of twitch force and pacing response 
frequency along with culture time. However, 2M patches with a greater signal volume index 
of connexin 43 when comparing with 4 and 6M patches gave the evidence to longer 
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spontaneous rhythmic contraction with 1-3M patches in contrast to just an arrhythmic 
contraction with 4-6M patches. In addition, all the patches manifested endothelia cell growth 
and a robust nuclear division. The present study demonstrates a spontaneously contracting 
cardiac patch fabricated by seeding neonatal cardiac cells on fibrin gel scaffold and its specific 
characteristics.  
2.1 Introduction 
Tissue engineering combines cellular and molecular biology with material and 
mechanical sciences to provide an alternative to organ and tissue transplants which are limited 
by the supply of donor organs. Engineered cardiac tissues, constructed with primary or stem 
cell-derived cardiac cells on a natural or synthetic scaffold, have tremendous potential to offer 
alternative treatment modalities in the healing process of large injured areas and in repairing 
congenital defects in hearts. By embedding a sufficient number of cells in the tissue and by 
providing additional tension support to the damaged area, they circumvent low rates of cell 
engraftment and poor cell survival which have occurred in present cell therapies (Sekine et 
al., 2011; H.-J. Wei et al., 2008; Wollert and Drexler 2010). 
Cardiac tissue constructs have been fabricated by embedding neonatal cardiac cells 
(Fujimoto et al., 2010; Kensah et al., 2011; W.-H. Zimmermann et al., 2006) with collagen 
type I supplemented with Matrigel, and by embedding pluripotent stem cell-derived 
cardiomyocytes with collagen type I gel, (Guo et al., 2006; Tulloch et al., 2011) poly-L-lactic 
acid and polylactic-glycolic acid gel, (Caspi et al., 2007) momentum flap (Kawamura et al., 
2013) and hydrogel (Liau et al., 2011). 
Some in vivo studies showed that these cardiac constructs improved cell survival, 
(Sekine et al., 2011; Kawamura et al., 2013) vascular network formation (Zhou and Graham 
2009) and cardiac function ( Zimmermann et al., 2006) though their twitch force and physical 
properties varied with scaffold materials, embedded cell densities, and culture conditions. 
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Neonatal cardiac cells possess a tremendous differentiation potential and regenerative 
capacity. The hearts of 1-day-old neonatal mice can regenerate after a partial surgical resection 
(Porrello et al., 2011). Fibrin is a natural, self-assembling peptide found in the body that is used 
to form clots along damaged endothelium. Fibrin gels possess high seeding efficiency, uniform 
cell distribution, and adhesion capabilities (Guyette et al., 2013; Swartz, Russell, and 
Andreadis 2005). It is formed by the reaction of thrombin and fibrinogen, which can be 
produced from the patient’s own blood, thus reducing the potential risk of rejection when used 
as a component in clinical application. We previously described a model for the self-
organization of primary cardiac cells on laminin substrate to form a cardioid, (Baar et al., 2005) 
which exhibited physiological performance metrics comparable to normal mammalian cardiac 
tissue. We then developed an engineered heart muscle by seeding or embedding 2-3 day old 
neonatal rat cardiac cells on the surface of, and within, a fibrin gel. Histological evaluation 
showed the presence of uniformly distributed cardiac cells throughout the engineered heart 
muscle tissue. The stimulated active force of this tissue by the seeding approach was 835.5 ± 
57.2 μN and by embedding 145.3 ± 44.9 μN (Y. Huang, Khait, and Birla 2007). The present 
study fabricated a cardiac tissue patch by seeding the neonatal rat heart cells on fibrin gel with 
the intent to optimize natural spontaneous contraction by evaluating cell densities and length 
of culture. Optimized patches will be used for in vivo grafting in future studies. 
2.2 Materials and Methods 
All animal protocols were approved by the Institutional Animal Care and Use 
Committee (IACUC) at University of Houston, in accordance with the “Guide for the Care 
and Use of Laboratory Animals” (NIH publication 86-23, 1996). All materials were purchased 
from Sigma-Aldrich (St. Louis, MO) unless otherwise specified. 
 
 
 12 
2.2.1 Isolation of primary cardiac cells 
Cardiac cells were isolated from the hearts of 2-3 day old neonatal Sprague-Dawley 
rat pups using an established method (Y. Huang, Khait, and Birla 2007). Each heart was cut 
into 3-4 pieces in an ice-cold phosphate buffer consisting of 116 mM NaCl, 20 mM HEPES, 
1 mM Na2HPO4, 5.5 mM glucose, 5.4 mM KCl and 0.8 mM MgSO4. After blood cells were 
rinsed out, heart pieces were transferred to a dissociation solution (Porrello et al., 2011) 
consisting of 0.32 mg/ml collagenase type 2-filtered (Worthington Biochemical Corporation, 
Lakewood, NJ) and 0.6 mg/ml pancreatin in phosphate buffer. The hearts were cut into 1 mm3
 
pieces and then transferred to an orbital shaker and maintained at 37
o
C for 30 minutes at 60 
rpm. At the end of the digestion process, the supernatant was collected in 3 ml of horse serum 
to neutralize the enzyme and centrifuged at 1000 rpm for 5 minutes at 4
o
C. The cell pellet 
was re-suspended in 5 ml horse serum and kept in an incubator at 37
o
C supplied with 5% 
CO2. Fresh DS was added to the partially digested tissue and the digestion process was 
repeated an additional 2-3 times. Cells from all the digests were pooled, centrifuged and 
suspended in culture medium (CM) consisting of M199 (Life Technologies, Grand Island, 
NY), with 20% F12k (Life Technologies, Grand Island, NY), 10% fetal bovine serum, 5% 
horse serum, 1% antibiotic-antimycotic, 40 ng/ml hydrocortisone and 100 ng/ml insulin. Cell 
viability was analyzed by Trypan blue (4%) staining according to the manufacturer’s protocol. 
2.2.2 Fabrication of artificial cardiac patch 
The method to fabricate the cardiac patch is shown in Figure 2A-H. A 35 mm tissue 
culture plate was coated with 2 ml of SYLGARD (PDMS, type 184 silicone elastomer) (Dow 
Chemical Corporation, Midland, MI). The plate was air dried for 2 weeks and sterilized with 
80% ethanol before use. Four minutien pins (Fine Science Tools, Foster City, CA), 0.1 mm 
diameter, were placed in the culture plate to form a 2 × 2 cm square. The fibrin gel was made 
by plating 1 ml of CM containing 10 U/ml thrombin and adding 500 μl of saline containing 20 
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mg/ml fibrinogen, and mixed well to promote gel formation within 10 minutes. Primary 
cardiac cells were diluted in CM at a pre-set density, and 2 ml of the cell suspension CM was 
transferred to the culture plate. Aminocaproic acid (2 mg/ml) was added to the culture plate to 
inhibit the fibrinolysis by endogenous proteases. The cells were cultured in an incubator at 
37
o
C and 5% CO2 with CM changes every other day. 
 
Figure 2:  Schematic methods for artificial cardiac tissue patch fabrication. 
 
2.2.3 Pacemaker cells, patch formation and contraction rate 
Sixteen hours after cell plating, pacemaker cells were counted manually from five 200× 
fields (center and top, right, left, and bottom most from the center of the patch) under an 
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inverted phase-contrast microscope (Olympus, Center Valley, PA). The total pacemaker cells 
of one patch from one density were averaged. The contraction of cultured cardiac constructs 
and fibrin gel detachment from culture plates were observed from day 1 to day 6, the patch 
growth progress was captured in still photographs and videos using a camera (Lumenera, 
Ottawa, ON) mounted on an inverted phase-contrast microscope. The videos were slowly 
replayed and the contraction rates manually counted. 
2.2.4 Contractile twitch force and electrocardiogram (ECG) 
From the first day of patch formation, spontaneous twitch force and the twitch force 
by electrical pacing (10V, 0.1s) were measured using a high sensitivity isometric force 
transducer (MLT0202, ADInstruments, Colorado Springs, CO) connected to a quad bridge 
amplifier (FE224, ADInstrument, Colorado Springs, CO). ECG signal was measured using 
Octal Bio Amp (ML138, ADInstrument, Colorado Springs, CO) within a thermostatic water 
bath. Data was acquired through a 16 channel PowerLab system (PL3516/P, ADInstruments, 
Colorado Springs, CO). As shown in Figure 2I and 2J, the contractile twitch force was 
measured by attaching the force transducer arm to one free-corner of the square patch, while 
the other three ends of the square patch were held fixed by pins. In order to obtain the Frank-
Starling relationship for the measured twitch force, pretension was adjusted using a micro-
manipulator (Radnoti LLC, Monrovia, CA) and measurements of spontaneous contraction 
were recorded. We defined that a spontaneous contraction rate of more than 120 bpm is high 
rate contraction, and that a spontaneous contraction rate of less than 20 bpm is low rate 
contraction. ECG of the patch was measured, as shown in Figure 2I, by inserting a needle 
cathode (MLA1213, ADInstruments, Colorado Springs, CO) into the center of the patch and 
a needle anode in one of the four patch corners. The media immersing the patch was used as 
ground. LabChart (ADInstruments, Colorado Springs, CO) was used for data analysis. The 
peak analysis module was used to calculate the maximal twitch force and baseline force 
(pretension). The ECG analysis module was used to calculate the R wave amplitude. Electrical 
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pacing was performed by attaching the stimulating electrodes (MLA0320, ADInstruments, 
Colorado Springs, CO) on the edge of patch tissue at frequencies of 0.25, 0.5, and 1-8 (in 1 
unit increments) Hz at 2, 4, and 6 days after patch formation. An effective electrical pacing 
frequency was determined by the initiation of a contraction. 
2.2.5 Morphology 
Seven days after plating, formed patches were cut diagonally. The diagonal edge of the 
triangular block was aligned with the edge of a slide. The cross section and the surface of the 
triangle block were photographed and the images were trace by ImageJ 1.47d (Wayne 
Rashand, National Institute of Health, USA) to get the area of the cross section, the thickness 
and the height of the triangular block, and then this triangle block was weighed. From the 
central part of the patch two 0.5 × 0.5 cm blocks were taken, placed in a peel-a-way disposable 
embedding mold (VWR International, Radnor, PA), frozen in liquid N2, and then immediately 
immerged in Tissue Tek OCT compound (VWR International, Radnor, PA) and placed in a –
80°C freezer. Once the OCT compound solidified, each sample was sliced using a cryostat 
(Thermo Fisher Scientific, Waltham, MA). Tissue cross- and planar-sections were cut at a 
thickness of 10 μm or 6 μm. The sections were placed on VWR
® 
Microslides for preparation 
of morphological and immunofluorescence examinations. Images from cross-sections of 6 μm 
thickness were taken directly under a phase contrast light microscope (Olympus, Center 
Valley, PA). For measurement of the “real cardiac layer” (a layer of cells and naturally 
produced extracellular matrix forming on top of the fibrin gel scaffold) thickness, 10 μm cross-
sections were stained with Masson’s trichrome reagents, according to manufacturer’s protocol, 
and images were taken under a light microscope. The distinct tissue layers were traced and 
thicknesses calculated with ImageJ. 
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2.2.6 Immunofluorescence 
For observation of endothelial cell growth, nuclear division and collagen type I 
distribution in the patch, fresh tissue patches were directly fixed in ice cold acetone for 10 
minutes. 1.0 ×1.0 cm tissue patch blocks from the center were trimmed and nonspecific epitope 
antigens were blocked and cell membranes permeated with 10% goat serum / 0.5% Trition X-
100 at room temperature for 45 minutes. Tissue patch blocks were then incubated in mouse 
anti- α-actinin antibody (Sigma, A7811) 1:200, rabbit anti-collagen type I (Abcam, ab34710) 
1:100, rabbit anti- von Willebrand factor (vWF) (Abcam, ab6994) 1:750, rabbit anti-ki 67 
(Abcam, ab66155) 1:100, or rabbit anti-connexin 43 (Cx43) 1:100 at room temperature for 2 
hours. Subsequently, tissue blocks were treated with goat anti-mouse and goat anti-rabbit 
secondary antibodies (Alexa Fluor 488, Alexa Fluor 546 and Alexa Fluor 633, Life 
Technologies, Grand Island, NY) 1:400 at room temperature for 1 hour. Nuclei were 
counterstained with 4,6-diamidino-2-phenylindole (DAPI) (2.5 μg/ml) for 5 min at room 
temperature. Fluorescent images were obtained with a Nikon C2
+ 
confocal laser scanning 
microscope (Nikon Instruments Inc., Melville, NY). For measurement of the volume indexes 
of gap junctions, collagens and myofibrils, signal volumes of Cx43, collagen type I and α-
actinin expressions were examined within 6 μm cross-sections. Two Z-stack scans from each 
sample were acquired with a signal depth of 8 μm over 33 frames. After determining specific 
thresholds for Cx43, collagen type I, and α-actinin, signal volumes for each sample were 
measured. The signal volume indexes of Cx43 (or collagen type I) for different cell densities 
were expressed as  
      𝐶𝑥43 𝑠𝑖𝑔𝑛𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑖𝑛𝑑𝑒𝑥 =  𝐶𝑥43 𝑠𝑖𝑔𝑛𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 / (𝛼 𝑎𝑐𝑡𝑖𝑛 𝑠𝑖𝑔𝑛𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 +  𝐶𝑥43 𝑠𝑖𝑔𝑛𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒)              (1) 
and averaged for each sample. 
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2.2.7 Statistics 
Results are presented as mean ± standard deviation. Chi-Square analysis was used to 
test frequency variables. Comparisons among groups were made with a one-way analysis of 
variance (ANOVA) followed by the Bonferroni post hoc comparison test. In all tests, 
differences were considered statistically significant at a value of p<0.05. 
2.3 Results 
2.3.1 Patch formation 
By the present established isolation method, cell viability was 81.0 ± 2.2% (n=16). The 
time required for patch formation was a function of the initial plating density. On day 4, 
formation was complete for 28.0% (n=7/25), 56.3% (9/16), and 40.0% (6/15) of patches with 
1, 3 and 5M densities, respectively; Pearson Chi-Square analysis indicated p = 0.195. On day 
6, formation was complete for 68.0% (17/25), 87.5% (14/16), and 60.0% (9/15) of patches 
with 1, 3 and 5M densities, respectively; Fisher’s Exact test demonstrated p = 0.232. 
2.3.2 Pacemaker cells and contraction rate 
After cell plating, live cardiac cells (Figure 3A, green arrow heads) scatter and attach 
to fibrin gels with a spindle-shaped morphology; however, dead cardiac cells (Figure 3A, red 
arrow heads) congregate with a sphere-shaped morphology. Each pacemaker cell (Figure 3A-
C, white arrows) contracts at its own rate. At 16 hours after plating, pacemaker cells in 1M 
density is less (9.4 ± 3.6, n=7) than that in 3M (16.9 ± 2.8, n=7, p<0.01) and 5M (23.1 ± 2.5, 
n=8, p<0.01) densities; compared with 5M density, pacemaker cells in 3M density is less too 
(p<0.01) (Figure 3D). 
Arrythmic contraction in separate areas of patches were observed and occurred due to 
uneven pacing from different pacemaker cells which compete with each other. Upon day 2 
after plating, spontaneous tissue contractions were observable under a microscope for 1-3M 
densities. The highest contraction rates appeared on days 4, 3 and 3 and they are 305 ± 54 
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(n=7), 330 ± 49 (n=8) and 374 ± 69 (n=9) bpm for 1, 2 and 3M densities, respectively. For the 
4-6M densities, spontaneous contractions were observable 1 day after plating. Their highest 
contraction rates were attained on day 2; the highest contraction rates for 4, 5 and 6M densities 
are 365 ± 52 (n=11), 405 ± 34 (n=11) and 410 ± 33 (n=12) bpm, respectively. The highest 
contraction rates for 1, 3 and 5M patches are illustrated in Figure 3E. Compared with 1M 
density, the highest contraction rates in 3 and 5M densities are significantly greater (p<0.05 
or p<0.01). However, on day 6, the contraction rate in 1M (243 ± 71 bpm, n=7) is significantly 
greater than that in 3M (32 ± 23, n=9) (p<0.01) and 5M (43 ± 78, n=11) (p<0.01) densities.  
 
Figure 3:  Pacemaker cells and spontaneous contraction rates, A, 1M density at 16 hours, B, 3M, 
                  C, 5M densities at 16 hours after plating, D, number of pacemaker cells, E, 
                  spontaneous contraction rates at 1-6 days, Values are mean ± SD; *p<0.05, **p<0.01 
 
2.3.3 Contractile twitch force and ECG 
High rate (>120 bpm) and low rate (<20 bpm) twitch forces were recorded from formed 
patches from day 4 to day 6. For 1, 2 and 3M patches, high rate rhythmic contractions were 
detected throughout the entire recording period (starting at the onset of pretension). Figure 4A 
shows rhythmic contraction from a 3M patch and Figure 4B demonstrates its synchronous 
ECG. The largest twitch force was recorded when the pretension was set between 1000 to 
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3000 μN. However, for 4, 5 and 6M patches, high rate arrhythmic contractions were detected 
for a few seconds after pretension loads were applied, after which low rate contractions were 
observed. Figure 5C, D show the arrhythmic contraction and its synchronous ECG from a 5M 
patch. 
 
Figure 4: Contractile force and ECG, A, Contraction from a 3M patch, B, ECG  
                 of A, C, Arrhythmic contraction from a 5M patch, D, ECG of C, E,  
                 F, average contractile forces, G, average R wave amplitude of high rate. 
 
The high rate contractile force recorded with a pretension range of 1000 to 3000 μN 
for 1 to 6M densities are 550 ± 120 μN (n=11) to 2806 ± 916 μN (n=10); the greatest high rate 
contractile force is 4443 μN from a 6M patch. The low rate contractile force recorded with a 
pretension range of 1000 to 3000 μN for 1 to 6M patches are 970 ± 132 μN (n=11) to 3346 ± 
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932 μN (n=10); the greatest low rate contractile force is 4917 μN from a 6M patch. When 
compared with 2M density patch (1463 ± 576 μN, n=11), the high rate contractile force of 4M 
(2602 ± 638 μN, n=9) and 6M (3346 ± 932 μN, n=10) patches are significantly greater (p<0.01) 
(Figure 5G). Likewise, the low rate contractile force of 2M patch (1710 ± 575 μN, n=10) is 
also significantly lower than that of 4M (3086 ± 804 μN, n=11) and 6M (3346 ± 932 μN, 
n=10) patches (p<0.01) (Figure 5H). Electrocardiograms of the patches exhibited natural QRS 
complex patterns, as evidenced by the representative 3 and 5M patches in Figure 4B and D. 
Figure 4G demonstrates the R wave amplitudes of high rate patches from 4M (24.4 ± 8.7 μV, 
n=10) and 6M (28.1 ± 6.4 μV, n=5) patches were greater than that from 2M (8.9 ± 8.1 μV, 
n=8) patch (p<0.01). 
2.3.4 Effect of culture time on contractile twitch force 
The effects of culture time on patch twitch force were examined for 4M density patch 
at 0, 2, 4 and 6 days after patch formation. High and low rate twitch force decreased during 
culture (Figure 6A, B). High rate twitch force on days 0, 2 and 4 are 2602 ± 638 (n=9), 1912 
± 898 (n=7) and 1530 ± 463 (n=5) μN, respectively. On day 6 high rate twitch forces were not 
detectable. Low rate twitch forces on days 0, 2, 4 and 6 are 3068 ± 804 (n=11), 1879 ± 822 
(n=11), 1509 ± 538 (n=8) and 1318 ± 279 (n=6) μN, respectively. A significant difference in 
high rate twitch force (p<0.05) was obtained between day 0 and day 4 (Figure 5C), A 
significant difference in low rate twitch force (p<0.01) was obtained between day 0 and days 
2, 4, and 6 (Figure 5D). Contractile response frequencies with 1-6M patches are synchronous 
with electrical pacing which can reach to the 1-6M patches’ maximal spontaneous contraction 
rate. Figure 5A shows a representative synchronous response frequency is 8 Hz obtained from 
a 4M patch at its formation. The mean synchronous response frequency for 4M patches on 
days 0, 2, 4 and 6 are 5.9 ± 0.8 (n=9), 5.6 ± 0.9 (n=9), 5.0 ± 0.8 (n=8) and 3.2 ± 1.0 (n=7) Hz, 
respectively. Synchronous response frequency decreases during culture (Figure 5B), and it is 
significantly smaller on day 6 relative to the other days (Figure 5E, p<0.01). The contractile 
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forces by 0.25 and 2 Hz electrical pacing for 4M patch, which correspond to the spontaneous 
low and high rate contractions, also decrease during culture (Figure 5F, G). However, no 
significant difference in the contractile force by 0.25 or 2 Hz pacing was observed when 
compared with low or high rate spontaneous contractile force on the same day points. 
 
Figure 5:  Effects of culture time and electrical stimulation on contractile pacing, A, twitch        
                 forces at time of formation, B, at 6 days, C and D, high and low rate contractile forces  
                 with culture time, E, electrical response, F and G, force with 0.25 and 2.0 Hz pacing.  
 
2.3.5. Morphology 
The physical properties of fibrin gel scaffolds of formed patches were examined on 
day 7. The cross-section area of the triangular patch tissue with 1-6M densities was 32.5 ± 2.8 
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mm
2 
(n=10), its thickness was 0.94 ± 0.13 mm (n=10), its height was 15.1 ± 2.1 mm (n=10), 
and its weight was 494 ± 43 mg (n=10), there are no significant differences in the cross-
sectional areas, patch thicknesses, heights and weights of the triangle blocks with 1-6M 
densities (p>0.05). The high and low rate contractile twitch forces are generated by one corner 
of patch tissue (half of the patch, a triangular block), therefore, for 6M density patch the high 
rate mean contractile force per m
3 
volume or per gram wet weight was calculated as 2086µN 
÷ (0.5 × 32.5mm
2 
× 15.1mm) = 8514 kN/m
3 
or as 2086µN ÷ 494mg = 4.22 N/g. By the same 
formula, the low rate mean contractile force for the 6M density is 14065 kN/m
3 
or 6.77 N/g; 
the high rate mean contractile force for 1M is 2245 kN/m
3 
or 1.11 N/g, and its low rate mean 
contractile force 3959 kN/m
3 
or 1.96 N/g. 
A layer of cardiac cells and self-produced extracellular matrix proteins, which we call 
the real cardiac layer, formed on top of the fibrin gel scaffold network (arrow heads, Figure 
6A) and the planar networks of fibrin gel scaffold are shown in Figure 6B. The thickness 
(arrow heads, Figure 6C) of the real cardiac tissue layer was further revealed by Masson 
trichrome staining though they were physically altered by fixing process. The positive staining 
for vWF (red) (Figures 6D) suggests that endothelial cells were growing and some endothelial 
cell grow together to be a congregation (Figure 6D, arrow), the positive staining for the ki67 
(white) (Figures 6E) suggests the presence of robust nuclear division, and the positive staining 
for the collagen type I (purple, Figure 6F) indirectly demonstrates the distribution of myoblasts 
within the cardiac tissue. A larger endothelial cell congregation within the patch is shown in 
Figure 6G and a dividing cardiac nucleus in karyokinesis is shown in Figure 5H (arrow). The 
positive staining for connexin 43 (yellow) (Figure 6I) indicates the intercellular coupling via 
gap junctions between cardiomyocytes. 
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Figure 6:  Patch morphology. A, cross-section, B, planar, C, cross-section Masson’s, D, IHC at  
                 20x E, nuclear division (Ki67), F, collagen type I within the constructs,  
                 G, congregation of endothelial cells (vWF), H a nucleus in karyokinesis. 
 
The real cardiac layer and part of the support fibrin scaffold stained with Masson’s 
trichrome from 2, 4 and 6M patches are shown in Figures 7A-C. The representative 
expressions of myofibrils by α-actinin staining and gap junctions by Cx43 staining for 2, 4 and 
6M patches are shown in Figures 7D-O. The average thicknesses of real cardiac layers for 2, 
4 and 6M were 18.2 ± 2.4 (n=13), 21.4 ± 1.4 (n=14) and 20.6 ± 2.4 (n=12) μm, respectively; 
there were significant differences when compared 4 and 6M (p<0.05 or p<0.01) with 2M 
(Figure 7P). The signal volume index of Cx43 was greater for 2M (0.182 ± 0.051, n=13), than 
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for 4M (0.132 ± 0.039, n=13) and 6M (0.126 ± 0.038, n=16) (p<0.05 or p<0.01) (Figure 7Q). 
The signal volume index of collagen type I was also calculated to be (0.221 ± 0.065, n=9), 
(0.209 ± 0.070, n=8) and (0.196 ± 0.050, n=15) for 2, 4 and 6M, respectively; however, there 
were no significant statistical differences (p>0.05). 
 
Figure 7:  Cardiac thicknesses and gap junctions. A, B, and C cross-section Masson’s trichrome  
                  stains, D, E and F cross-sections IHC stains, G, J, M total signal volumes, H, K, N  
                  Cx43, I, K, O α-actinin, P, cardiac layer thickness, Q, signal volume index of Cx43. 
 
2.4 Discussion and Conclusion 
Fibrin is a natural biopolymer with many interesting properties, such as 
biocompatibility, bioresorbability, ease of processing, ability to be tailored to modify the 
conditions of polymerization, and potential incorporation of both cells and cell mediators 
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(Barsotti et al., 2011). Cardiac cell sheet transplantation improves damaged heart function via 
superior cell survival in comparison with dissociated cell injection. Native, fully-hydrated 
fibrin gels can form at different fibrinogen and thrombin concentrations and at different ionic 
strengths (Blombäck et al., 1989). Fibrin alone, or in combination with other materials, has 
been used as a biological scaffold for stem and primary cells to regenerate adipose tissue, 
bone, cardiac tissue, cartilage, liver, nervous tissue, ocular tissue, skin, tendons, and ligaments 
(Ahmed, Dare, and Hincke 2008). The fibrin support scaffold in the present study was 
developed with human fibrinogen and thrombin. Under a light microscope, a thin layer of real 
cardiac tissue (Figure 7A, C) was seen on the top of fibrin gel network, the thickness of the 
real cardiac layer varied with the plated cell density, with the 4 and 6M patches having a 
significantly thicker layer than the 2M patches (Figure 7P). The reason for this difference 
might result from the different initial cell densities and/or the growth rate of each cell type 
within the patch. 
Freshly isolated neonatal cardiac cells consist of myoblasts, cardiomyocytes, smooth 
muscle cells, endothelial cells and cardiac stem cells. The proliferation rate of cardiac cells is 
higher in the fetal stage than in the neonatal stage, and greatly diminishes in adulthood 
(Anversa et al., 2013; Fujimoto et al., 2010). We used 2 to 3-day-old rat heart cells to construct 
our patch. As shown in Figures 7D, E, and I, specifically in G, endothelial cells and endothelial 
cell congregation, positively stained by vWF which is secreted by the endothelial cells lining 
blood vessels, (Ruggeri 1999) were growing in the cultured cardiac patches. A positive 
staining for vWF demonstrated that there were potential angiogenesis buds, which would be 
suitable to grow and connect to host micro blood vessels and bring nutrients into the patch 
during in vivo applications. There were signs of robust cell proliferation in this patch, which 
were revealed by nuclear division and marked by ki67 positive staining (Figures 6E, H). Ki67 
is a nuclear protein which is tightly associated with somatic cell proliferation (Endl and Gerdes 
2000). 
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The Cx43 positive staining indicates that cardiomyocytes in the present cardiac tissue 
patch exhibit electromechanical coupling (Figure 6I, 7D-F). The detected ECG signal and the 
natural, adult-heart-like QRS complex revealed that these patches can sustain electrical 
propagation with speeds that would be close to native tissues. The R wave amplitudes 
increased with thickness of real cardiac tissue; as shown in Figure 4B, D and G, 4 and 6M 
patches exhibit greater R wave amplitude than 2M patch because they possess more 
cardiomyocytes, which can generate a higher depolarization current. 
Dishes with higher cell densities (4 to 6M) began localized spontaneous contractions 
earlier, after only 1 day of incubation. The average contraction rate for 6M density was 410 ± 
33 bpm (n=12) on day 2, which falls within the range of a normal adult rat heartbeat. For 1, 2 
and 3M densities, the highest mean contraction occurred on days 4, 3 and 3, respectively, and 
then steadily decreased from day 5 to 6. For 4 to 6M densities, the highest contraction rates 
occurred much earlier, on day 2 but it decreased sharply from day 3 to 6. As shown in Figure 
3A-C, the number of viable cardiac cells (Figure 3A, green arrow heads) that attached to the 
fibrin gel was dependent on the initial plating densities. Sixteen hours after plating, the 
pacemaker cells for five 200× fields with 1M density is less than 3 and 5M densities (Figure 
3D, p<0.01), and that with 3M density is less than 5M too (Figure 3D, p<0.01). Supplemental 
movie 1 was taken 36 hours after cell plating from a 3M density, which shows the pacemaker 
cells are pacing at different frequencies and so they will compete with each other. After a few 
more days of incubation, the various frequencies coalesce into a single contraction frequency 
for the majority of the patch, this results adheres to a synchronization phenomenon that is 
dependent on the number of initial pacemaker cells and the conduction of their action 
potentials. The surrounding cardiac tissue comes from the proliferation of the initial seeding 
myoblasts and the limit dividing of initial seeding myocardiocytes. When it is ready, the 
dominate fast-speed pacemaker cells can propagate their action potential and initiate the whole 
tissue contraction. High density cardiac cell plating supplies more high-rate pacemaker cells, 
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cardiomyocytes and myoblasts. Figure 3E shows that it took 4 days for the pacemaker cells 
with 1M density to reach maximal contraction rate at 305 ± 54 (n=7) bpm and then plateaued 
at (average of last day 5 and 6); however, it took only 2 days for the pacemaker cells with 5M 
density to reach maximal contraction rate of 405 ± 34 (n=11) bpm and plateaued at a 
significantly lower frequency of (average of day 4, 5, and 6). 3M density dishes may have 
possessed an ideal proportion of cardiomyocytes to myoblasts, thus allowing them to reach 
their maximal contraction rate early. This may be the explanation for 3M density dishes having 
completely formed 56.3% of patches on day 4 and 87.5% patches on day 6, which were 
quicker than 1M and 5M dishes. 
A synchronized contraction relies on the appropriate proportion of cardiomyocytes to 
myoblasts as well as smooth muscle cells and endothelial cells. In the present study, patches 
with 1 to 3M densities presumably maintained the appropriate cell-type proportion that 
enhanced the synchronization and increased the contraction rate. Because the myoblasts 
proliferate faster than cardiomyocytes, after day 3 or 4 the appropriate proportion no longer 
existed. The aging and apoptosis of the pacemaker cells and the myoblast overpopulation and 
the mismatch of contraction cells with extracellular matrix are the main causes for a decrease 
in contraction rate by affecting the initiation of pacemaker cells, the efficiency of gap junctions 
and delaying the propagation of action potential. The varying rates of proliferation between 
myoblasts and cardiomyocytes could also partially explain why steady contractions were 
detected from 1 to 3M patches, while more arrhythmic contractions were detected from 4 to 
6M patches. 
The strength of a muscle’s contraction is influenced by the number of fibers within the 
muscle that have interactions of myosin cross bridges with actin, the rate of contraction, and 
the relaxed length of the muscle fibers. We treated the present cardiac tissue patch as a whole 
functional unit and analyzed the contractile forces generated by the 1-6M patches. The real 
cardiac tissue layers of 4 and 6M patches were thicker than 2M (Figure 7P); however, the 
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signal volume indexes of collagen type I within the 3 densities were not significantly different. 
This suggests that the myofibril content in 4 to 6M patches may be higher than that in 2M 
patches. As such, the difference in myofibril content may explain the greater twitch forces 
generated from the 4 to 6M patches than the 2M one. Based on the results for percentage of 
complete formation of patches on days 4-6, contractile force, and thickness of the real cardiac 
layer, a 3 or 4M patch is the optimal choice for future in vivo study. 
The reasons for the decreases of response frequency due to electrical pacing and twitch 
force presumably resulted from the aging and apoptosis of cardiomyocytes, and inappropriate 
proportion of cardiomyocytes to surrounding matrix caused by the overpopulation of 
myoblasts. To determine the underlying mechanisms for arrhythmic contractions exhibited in 
4-6M patches, we examined the signal volume index of the gap junction protein Cx43. Our 
results revealed a statistical difference of Cx43 signal volume indexes in 4 and 6M patches 
when compared with 2M one (p<0.05 or p<0.01) (Figure 7Q). Cx43 is the major protein of 
cardiac ventricular gap junctions and is crucial to cell-cell communication and cardiac function 
(Boengler, Schulz, and Heusch 2006).  
Recent works reported that changed expression of Cx43 might contribute to a higher 
level of arrhythmogenicity (A Salameh et al., 2009; Severs et al., 2008). Criteria for cardiac 
tissue constructs have been proposed by Zimmermann’s group (W.-H. Zimmermann, 
Melnychenko, and Eschenhagen 2004). These constructs should display functional and 
morphological properties similar to native heart muscle and remain viable after implantation. 
The present 3-4M density cardiac constructs possess adult-heart-like spontaneous contraction. 
Endothelial cell growth, robust cellular division, and electromechanical coupling proteins 
were all observed. This will allow for invagination of host vasculature and electrical 
propagation. When it is applied to in vivo transplantation, this artificial graft may not only 
supply enough tension support but also conduct action potential and synchronously contract 
with the host muscle. Furthermore, it is possible to use host origin fibrinogen and thrombin 
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to produce non-immunogenic fibrin scaffolds before in vivo application. However, the 
thickness, longevity, and synchronicity of the present patch model are limited due to low 
levels of nutrient supply within the scaffold network. Future enhanced nutrient delivery will 
result in a stronger and more energetic artificial cardiac constructs. 
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Chapter 3: Bioartificial Heart 
Establishing the Framework to Support Bioartificial Heart 
Fabrication Using Fibrin-Based 3D Artificial Heart Muscle 
 Only 3,000 heart transplants are performed in the U.S. every year leaving some 30,000-
70,000 Americans without proper treatment. Current treatment modalities for heart failure have 
saved many lives yet still do not correct the underlying problems of congestive heart failure. Tissue 
engineering represents a potential field of study wherein a combination of cells, scaffolds and/or 
bioreactors can be utilized to create constructs to mimic, replace and/or repair defective tissue. The 
focus of this study was to generate a basic framework for a bioartificial heart (BAH) using artificial 
heart muscle (AHM), composed of fibrin gel and neonatal rat cardiac myocytes, and a 
decellularized scaffold, formed by subjecting an adult rat heart to a series of decellulurization 
solutions. By suturing the AHM around the outside of the decellularized heart and culturing 
suspended in media, we were able to generate a construct with the primary rudiments of form and 
function in a native heart. Visible contractility was correlated with biopotential measurements to 
confirm basic functionality of the constructs. Cross-sections of the hearts show successful 
decellularization of the scaffold and contiguous cell-containing AHM around the perimeter of the 
heart. The study outlines the methods for the successful generation of a novel framework for a BAH 
construct. 
3.1 Introduction 
Heart disease is one of the most important medical concerns in this country and is the 
leading cause of death in the United States. Around 5.7 million people live with heart disease in 
the United States (Members et al., 2012). Managing these patients accrues costs of nearly 34 billion 
per year. Coronary heart disease causes about 1 in every 9 deaths in this country. It has been 
estimated that 30,000 to 70,000 Americans each year would benefit from a heart transplant that 
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they could not get (Copeland et al., 2004). Conversely, only about 3,000 heart transplants are 
performed in the U.S. every year. 
A variety of heart disease treatment modalities have been explored and are clinically 
available. Mechanical assist devices have been used in order to bypass or replace failing hearts. 
Left ventricular assist devices (LVAD) are mechanical pumps designed to increase cardiac output 
(Bond et al., 2003). Similarly, total artificial hearts (TAH) are mechanical pumps designed to 
bypass the function of the entire heart, effectively serving as a bridge to heart transplant (Platis and 
Larson 2009). LVAD and TAH treatments are limited by bio-incompatibility, device failure and 
absence of bio-integration. Pharmaceutical agents have been developed to combat some of the 
symptoms of heart disease. ACE inhibitors, diuretics, vasodilators, digitalis preparations, blood 
thinners and calcium channel blockers are all cardiovascular medications used for the treatment of 
heart disease. Unfortunately, these medications typically treat the symptoms of heart disease and 
do little to combat the underlying problem of damaged cardiac tissue. 
Presently, the only long-term solution to heart failure is organ transplantation. 
Unfortunately, there are far too few donor hearts to meet this need. Due to the rapid deterioration 
of excised tissue, donor hearts must be used within several hours of explantation. This can make 
planned procedures very difficult and reduces the efficacy of treatment for end stage heart failure. 
Furthermore, donor and recipient must be matched for blood type and body size in order to reduce 
risk of rejection. The lack of donor hearts, along with the difficulty of scheduling and prohibitive 
costs of heart transplants contribute to the inadequacy of heart transplant procedures as effective 
means of cardiovascular disease treatment. 
In the field of regenerative medicine, researchers attempt to develop methods to circumvent 
current clinical limitations. Archundia et al. and Amado et al. experimented with direct injection 
of cells for cardiovascular regeneration (Archundia et al., 2005; Amado et al., 2005). Another 
common regenerative medicine approach involves introduction of tissue inducing substances in 
vivo. Hayashi et al. developed scaffolds designed to promote endogenous bone growth (Hayashi et 
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al., 2009). Tissue engineering is an interdisciplinary field applying the principles of engineering to 
biological components. In the field of tissue engineering, a combination of cells, scaffolds and/or 
bioreactors are used in order to create a construct designed to emulate native tissues (Langer and 
Vacanti 1993). Complex biomimetic tissues can also be created in vitro using combinations of cells, 
scaffolds, and bioreactors, which mimic in vivo conditions (Shachar, Benishti, and Cohen 2012). 
The field provides many promising potential research avenues for treatment alternatives to 
conventional therapies. 
Our lab has extensive experience with regards to the creation of AHM tissues and 
cardiovascular components (Evers, Khait, and Birla 2011; Birla, Hollister, and Migneco 2008; L 
Khait and Birla 2007; Baar et al., 2004; Blan and Birla 2008; Y.-C. Huang, Khait, and Birla 2007). 
Using laminin as a scaffold on PDMS coated dishes, Baar et al. created self-organized contractile 
3D cardiac tissue using neonatal cardiac myocytes (Baar et al., 2004). Deemed cardiods, this work 
produced one of the first 3D cardiac muscle tissue constructs capable of generating a contractile 
force of roughly 140 μN (Baar et al., 2004). Using a porous chitosan scaffold and rat neonatal 
cardiac cells, Blan and Birla created a smart material integrated heart muscle (SMIHM) with a 
maximum contractile twitch force of 439.5 μN (Blan and Birla 2008). Using fibrin gel as a scaffold, 
Huang, Khait and Birla created bioengineered heart muscle (BEHM) with an active twitch force of 
~835 μN (Y.-C. Huang, Khait, and Birla 2007). Most recently, our group developed a fibrin based 
AHM with structural similarity to native heart muscle tissue capable of generating an active twitch 
force upwards of 4 mN. 
We plan on capitalizing on our expertise in AHM generation for the development of a 
framework for a bioartificial heart. BAHs are a potential alternative therapy for end stage heart 
failure using decellularized hearts as a scaffold for functional cardiac myocytes (Gilbert, Sellaro, 
and Badylak 2006; Ketchedjian et al. 2005). If properly seeded and conditioned, decellularized 
constructs can function as basic pumps providing a model for a total artificial heart (Black et al., 
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2008). The focus of this study is the production of a BAH using fibrin gel based AHM sheets and 
decellularized heart scaffolds. 
 
Figure 8:  Protocol for the generation of a BAH using AHM. 
 
3.2 Materials and Methods 
All animal protocols were approved by the Institutional Animal Care and Use Committee 
(IACUC) at the University of Houston. All materials were purchased from Sigma-Aldrich (St. 
Louis, MO) unless otherwise specified.  
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 3.2.1 Decellularization of scaffolds 
Rat hearts were obtained from 3-6 month old Sprague-Dawley rats and immediately 
washed in a phosphate buffered saline 
solution to prevent blood coagulation. The 
hearts were then sequentially incubated in 
15 mL of a series of decellularization 
solutions as indicated in Table 1 and shaken 
at 60 RPM in an orbital shaker at 25°C over 
the course of 14 days. 
3.2.2 Isolation of primary cardiac cells 
Cardiac cells were isolated from the hearts of 2-3 day old neonatal Sprague-Dawley rats 
using an established method. Each heart was cut into 3-4 pieces in an ice-cold phosphate buffer 
consisting of 116 mM NaCl, 20 mM HEPES, 1 mM Na2HPO4, 5.5 mM glucose, 5.4 mM KCl and 
0.8 mM MgSO4. The pieces were gently rinsed in order to remove blood and transferred to a 
 
Figure 9:  Decellularization process of a rat heart, Progress of decellularization of the rat hearts  
                  at 2-day increments over 14 days.  
Table 1: Decellularization protocol 
  Components Schedule 
Solution 1 
80% Glycerol* 
0.9% NaCl 
0.05% NaN3 
25 mM EDTA 
Day 0-2 
Solution 2 
4.2% sodium deoxycholate 
0.05% NaN3 
Day 2-4 
Solution 3 
1% SDS 
0.05% NaN3 
Day 4-6, Day 8-10 
Solution 4 .05% NaN3 Day 12-14 
Solution 5 
3% Triton X-100* 
0.05% NaN3 
Day 6-8, Day 10-12 
*By volume 
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secondary phosphate buffer solution. Tissues were minced into 1 mm3 pieces and transferred to a 
dissociation solution (DS) consisting of filtered 0.32 mg/ml collagenase type 2 (Worthington 
Biochemical Corporation, Lakewood, NJ) and 0.6 mg/ml pancreatin in phosphate buffer. A 50 mL 
conical tube containing 15 mL of DS and the minced tissues was placed in an orbital shaker and 
maintained at 37°C for 30 minutes at 60 rpm. At the end of the digestion process, the supernatant 
was collected in 3 ml of horse serum to neutralize the enzyme and centrifuged at 1,000 rpm for 5 
minutes at 4°C. The cell pellet was re-suspended in 5 ml horse serum and kept in an incubator at 
37°C supplied with 5% CO2. Fresh DS was added to the partially digested tissue and the digestion 
process was repeated an additional 2-3 times. Cells from all the digests were pooled, centrifuged 
and suspended in culture medium (CM) consisting of M199 (Life Technologies, Grand Island, NY), 
with 20% F12k (Life Technologies), 10% fetal bovine serum, 5% horse serum, 1% antibiotic-
antimycotic, 40 ng/ml hydrocortisone and 100 ng/ml insulin. Cell concentration and viability was 
assessed by Trypan blue (4%) staining according to the manufacturer’s protocol.    
3.2.3 Fabrication of AHM 
The heart muscle was fabricated using a fibrin gel and neonatal cardiac myocytes (Figure 
8 and Figure 10). A 35 mm tissue culture plate was coated with 2 ml of SYLGARD (PDMS, type 
184 silicone elastomer) (Dow Chemical Corporation, Midland, MI). The plate was air dried for 2 
weeks and sterilized with 80% ethanol before use. Eight minutien pins (Fine Science Tools, Foster 
City, CA), 0.1 mm diameter, were placed in the culture plate to form a regular octagon with a radius 
of 1.3 cm, a square with 2 cm and a square with 3 cm edges. Mixing 1 mL of CM containing 10 U 
thrombin/mL with 500 μL of saline containing 20 mg/mL fibrinogen in a PDMS coated petri dish 
allowed for the formation of a fibrin gel scaffold. The petri dishes were shaken well to promote 
mixing and placed in the incubator in order to promote gel formation within 15 minutes. Cells were 
seeded with a density of 4M per plate. Epsilon-aminocaproic acid (2 mg/mL) was added to the 
culture plate to inhibit the fibrinolysis by endogenous proteases. The cells were cultured in an 
incubator at 37°C and 5% CO2 with CM changes every two days. 
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Figure 10:  Photographs of Stages of the Artificial Heart Formation Process, The left side of the  
                    figure illustrates the stages in the AHM fabrication process and the right side shows  
                    the various steps when constructing the total bioartificial heart. 
 
3.2.4 Contractile twitch force of AHM 
From day 4, twitch force was measured using a high sensitivity isometric force transducer 
(MLT0202, ADinstruments, Colorado Springs, CO), connected to a quad bridge amplifier (FE224, 
ADinstrument, Colorado Springs, CO). Data acquisition was performed through a 16 channel 
PowerLab system (PL3516/P, ADInstruments, Colorado Springs, CO). The force transducer arm 
was attached to one free-corner of the patch, while the other ends were held fixed; spontaneous 
measurements were recorded for 30-60 seconds. Pretension was adjusted using a micro-
manipulator (Radnoti LLC, Monrovia, CA) and measurements of spontaneous contraction were 
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recorded. A Stable-Temp hotplate (Cole-Parmer, Vernon Hills, IL) was used to maintain media 
temperatures at 37°C throughout the course of measurement. LabChart’s (ADInstruments, 
Colorado Springs, CO) peak analysis module was used to calculate the maximum twitch force and 
baseline force (pretension).  
3.2.5 BAH formation 
Decellularized heart scaffolds were washed 3 times and placed in PBS 24 hours prior to 
construct formation to wash out decellularization solutions. At 4-6 days after plating, most AHM 
tissues were fully formed. The anchoring minutien pins were gently removed from the AHM. The 
artificial muscle was then lifted using two forceps and delicately inverted on the petri dish surface. 
Artificial heart tissues were re-pinned to the PDMS using minutien pins. The decellularized heart 
scaffolds were placed on the inverted tissues. The AHM was unpinned and gently sutured around 
the outside of the decellularized scaffolds using sterile 6-0 polypropylene sutures (AD Surgical, 
Sunnyvale, CA). The completely wrapped construct was suspended in a 50 mL conical tube by a 
1/16” diameter tubule inserted through the aorta of the decellulularized construct. Subsequently, 15 
mL of CM was added along with ε-aminocaproic acid (2 mg/ml), and the construct was placed in 
an incubator at 37°C and 5% CO2 with CM changes every two days and observed periodically for 
contraction. 
3.2.6 Contraction 
 Bioartificial hearts were examined daily for contractile action using an inverted phase-
contrast microscope (Olympus, Center Valley, PA). Hearts were removed from culture and placed 
in a small amount of CM in a 60 mm petri dish coated with PDMS. Still photographs and videos 
were captured using a camera (Lumenera, Ottawa, ON) mounted on a light microscope. (Olympus, 
Center Valley, PA). 
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3.2.7 Biopotential measurement 
 Biopotential measurements were observed through the direct application of 8 electrodes to 
the construct after a period of culture. Constructs were placed in a PDMS coated petri dish with 
warmed media. A Stable-Temp hotplate (Cole-Parmer, Vernon Hills, IL) was used to maintain 
media temperatures at 37°C throughout the course of measurement. Eight electrodes were pierced 
into the construct in a 4x2 grid with 2.54 mm of space horizontally between each electrode column 
and 3.8 mm of space vertically between each row. A reference wire was secured in PDMS in direct 
contact with the media at the edge of the dish. Electrodes were connected to an Octal Bio Amp 
(ML138, ADInstruments, Colorado Springs, CO). Data acquisition was performed through a 16 
channel PowerLab system (PL3516/P, ADInstruments, Colorado Springs, CO). LabChart 
(ADInstruments, Colorado Springs, CO) was used to output the 8 measured channels into a table 
with a sampling rate of 1000 Hz over 2 minute periods. Matlab (Mathworks, Natick, MA) was used 
to analyze and process the data. A moving average smoothing function with an 8% span was applied 
to the data for all 8 channels to reduce noise. 
3.2.8 Histology 
Histology was performed on natural and fully decellularized rat hearts, and BAHs after 6 
days of culture. Samples were all washed in PBS and gently patted dry using VWR® light-duty 
tissue wipers. Samples were suspended upright in a peel-a-way disposable embedding mold (VWR 
International, Radnor, PA) and submerged in liquid nitrogen for several seconds. Samples were 
then covered with Tissue Tek OCT (VWR International Radnor, PA) and placed immediately into 
a -85°C freezer. Once samples were completely solid, each sample was cross-sectioned using a 
cryotome (Thermo Fisher Scientific, Waltham, MA). Tissue samples were cut at a thickness of 10-
40 µm and placed on VWR® microslides. Cross-sections were stained with Masson’s trichrome 
and H&E reagents according to manufacturer’s protocol, and images were taken under the light 
microscope. 
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3.2.9 Immunohistochemistry 
Samples were frozen in OCT compound and sectioned to 10-40 μm thicknesses and placed 
on VWR® microslides. Cross-sections were fixed in ice cold acetone for 10 minutes; nonspecific 
epitope antigens were blocked with 10% goat serum at room temperature for 1 hour. Sections were 
incubated with mouse anti-α-actinin monoclonal antibody (Sigma, Catalog No A7811) 1:200 and 
rabbit anti-collagen type I (Abcam, ab34710) 1:100 at room temperature for 1 hour. Subsequently, 
sections were treated with goat anti-mouse and goat anti-rabbit secondary antibodies (Alexa Fluor 
488 and Alexa Fluor 546, Life Technologies, Grand Island, NY) 1:400 at room temperature for 1 
hour. Nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI) (2.5 μg/ml) for 5 min 
at room temperature. Fluorescent images were obtained with a Nikon C2+ confocal laser scanning 
microscope (Nikon Instruments Inc., Melville, NY). Z-stack images were taken in order to examine 
3D structures of sample slices with more than 20 μm thicknesses. 
3.3 Results 
3.3.1 Patch formation 
Established cell isolation methods were used to harvest cells with a viability of 81.0 ± 2.2% 
(n=16). Delamination typically began at day 3 with patch formation usually completing by day 4 
or 5. Contractile forces of patches plated with 4M cells using this method measured up to ~3,000 
μN. Patches exhibited macroscopic spontaneous contractions after 2 days of culture. The frequency 
of spontaneous contraction was in the range of 1-5 Hz. Patches were observed to contract 
continuously and actively for upwards of 3 weeks. 
3.3.2 Decellularization 
Hearts isolated from adult Sprague Dawley rats were subjected to a series of 
decellularization solutions as outlined in Table 1. The hearts became noticeably clearer and more 
translucent at each stage in the process (Figure 9). Hearts at day 0 and 14 of the decellarization 
process were sectioned and stained with H&E and Masson’s trichrome staining (Figure 11 and 
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Figure 12). Sections of hearts at day 0 in the decellularization process exhibited typical H&E and 
Masson’s trichrome patterns for untreated rat hearts. Masson’s trichrome stains at day 14 contained 
only blue stains and revealed no nuclei. H&E stains at day 14 in the process showed only red stained 
networks with no nuclei.  
 
3.3.3 BAH formation 
Decellularized hearts were washed in PBS in order to remove sodium azide from the 
structures. Sodium azide typically lyses cells and if not washed, destroys viable cells from AHMs 
removing functionality of the construct. Patches were treated gently in order to avoid destroying 
fragile cardiac myocytes. Constructs were formed using both inverted and non-inverted heart 
muscle formation techniques. Cells tend to aggregate on the upper layers of the fibrin gel using 
normal AHM formation techniques. Inverting the heart muscle prior to wrapping exposed the 
majority of the functional cells to the outer surface. When heart muscle tissue was inverted, there 
 
Figure 11: Histology of the Bioartificial Hearts (H&Es), H&E stains of a cross section of the  
                   total bioartificial heart. Cell nuclei are stained black and eosinophilic structures such  
                   as fibrin and collagen are stained pink. 
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was a noticeable increase in frequency of contraction of the artificial heart constructs viewed under 
the light microscope when compared with non-inverted muscle tissues.  
 
Figure 12: Histology of a cross section of the Bioartificial Heart (Masson’s trichrome), A  
                   stitched image consisting of 28 4x images of a Masson’s trichrome stained cross- 
                   section of a BAH.  
 
3.3.4 Contraction of BAH 
 After wrapping the patches around the outside of the decellularized hearts and securing 
them with sutures, contraction frequency would diminish or temporarily halt. After culturing the 
constructs for 1-2 days, contraction would resume at or near pre-wrapping frequency. Noticeable  
contractility was observed around the entire area of the heart under an inverted microscope. 
Observed contractile frequencies of beating BAHs ranged from 0.3 to 5 Hz. 
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3.3.5 Morphology 
 
Figure 13: Histology of the BAH, A, Masson’s trichrome of adult rat heart, B, Masson’s of a  
                   decellularized heart, C, H&E of a BAH, D, IHC (α-actinin, DAPI) of BAH, E, IHC  
                   (collagen) of decelluarized heart, F, cross section IHC stain of a BAH. 
 
Cross-sections stained with H&E were positive for nuclear stain around the acellular 
scaffold, indicating the presence of cardiac cells (Figure 11). The cell-rich AHM layer is visible 
around the perimeter of each image. The interior portion contains completely decellularized ECM. 
Masson’s trichrome stained cross-section of a BAH were imaged and stitched to visualize an entire 
cross-section (Figure 12). The exterior layer contains red stained fibrin gel and black stained cell 
nuclei. The interior portion is completely decellularized ECM with no noticeable black spots. 
3.3.6 Immunohistochemistry 
Confocal images contained fluorescently labeled structures highlighting collagen type I, α-
actinin and cell nuclei (Figure 13D and F). Confocal images of the decellularized scaffold showed 
a collagen rich network with many apparent empty spaces dispersed throughout the network (Figure 
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13A). A cell rich layer containing collagen (yellow) α-actinin (green) and DAPI (blue) was found 
around the perimeters of the stained sections (Figure 13B). 
3.3.7 Biopotential measurements 
Synchronous contractility was observed across 8 electrode channels in a waveform pattern 
consistent with native heart muscle (Figure 14). The sample measurement indicated a contractile 
rate of approximately 4.5 Hz with biopotential amplitudes in the range of 10-200 μV.  
 
Figure 14: Biopotential measurements of a beating BAH, A, Biopotential measurements over  
                   time for 8 electrodes, B, Schematic of the approximate placement of each electrode  
                   throughout the BAH sample, C, Unfiltered readout, D, Smoothed signal fit 
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3.4 Discussion and Conclusion 
The method used to generate patches in this study represents a novel tissue engineering 
protocol for the generation of AHM. Confocal analysis of the AHM indicates structural similarity 
to native heart muscle, (Figure 13B) and measured twitch forces represent a high degree of 
functionality. Fibrin gel was used as a scaffold as the two main components, fibrinogen and 
thrombin, can be isolated from human blood so patient specific scaffolds can be created. Use of 
minutein pins to control the geometry of the final patch gives us the ability to control AHM shape 
to fit a particular application. Throughout the course of this study, AHMs were generated in a 
variety of square sizes (2 - 3 cm2) and in an octagonal geometry. Octagonal geometries afforded 
the most efficient means of coverage of the perimeter of decellularized rat hearts while requiring 
the fewest resources. High twitch forces along with a readily reproducible and bioactive scaffold 
render our AHM model an efficient mechanism for delivery of cells to a structurally sophisticated 
scaffold. 
The decellularization process occurred over the course of 14 days (Figure 9). 
Decellularization solutions were not actively perfused through the hearts as in previous studies 
(Black et al., 2008). Simple submersion and agitation was used in order to increase the throughput 
of the method. After completion of the decellularization process, the remaining extracellular matrix 
structures appeared macroscopically intact. Vessels, ventricles and atriums are visible inside of the 
translucent structures. H&E and Masson’s trichrome stains of the decellularized constructs show 
striated ECM networks with no cellular presence (Figure 11). Confocal images of the decellularized 
scaffold show a collagen rich network containing no cells. High-resolution images reveal empty 
spaces ~5-10 μm in diameter where cells were located prior to decellularization of the heart (Figure 
13A). Effective decellularization of the hearts indicates the efficiency of the decellularization 
protocol. 
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There are two phases to the overall process for the formation of a BAH (Figure 10). AHM 
formation is the phase in which the functional components of the construct are created. The second 
phase of construct formation involves decellularization of the scaffold and subsequent attachment 
of the functional component. AHM represents an effective delivery vehicle for functional 
cardiomyocytes to the decellularized scaffold. Passive seeding of cells into a decellularized matrix, 
through coating or injection is an inefficient process, as most cells wash out of the matrix. (Black 
et al., 2008). The biologically active fibrin matrix contains functional sites at which cells can bind 
more readily. Physically combining the AHM with a structurally complex decellularized scaffold 
represents an alternative strategy for delivery of cells to a biologically similar matrix. 
After the AHM is formed, it is inverted and a decellularized heart is placed on the surface. 
Cells aggregate on the upper surface of the fibrin gel in an AHM. Inverting the AHM exposes the 
cells to the outer surface thereby insuring more effective nutrient delivery from CM to the cells of 
the AHM. Initial studies performed without inversion of the AHM resulted in lower contraction of 
the construct. We hypothesize that this is due to limited nutrient delivery. After attachment of the 
AHM, BAHs were placed in static culture during which they experienced a period of latency of 1-
2 days with no observable contraction. After culture for 4 days, slight pulling of the exterior AHM 
did not cause the fibrin layer to detach from the decellularized surface. This indicates some degree 
of interaction between the fibrin scaffold and ECM of the decellularized heart. 
Noticeable contractility was observed around the entire perimeter of BAH constructs. 
While the contraction was typically microscopic, observable contraction indicates retention of basic 
myocardial function. Introduction of electrical pacing and perfusion may improve contraction rates 
and overall contractile force. Continually, only 4 million cells were used in order to produce the 
AHM tissue, while a typical adult rat heart is estimated to have approximately 100 million cells 
(Rakusan et al., 1984; Banerjee et al., 2007). 
Confocal staining of cross-sections of the samples indicated 3 main components: a cell-
rich layer, a fibrin scaffold and a decellularized matrix (Figure 13). Positive stains for α-actinin, a 
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protein found in Z-discs of cardiac muscle, confirm the presence of cardiomyocytes in the BAH 
constructs. Positive collagen stains indicate healthy cells in the cell-rich layer. Furthermore, the 
collagen network visualized in confocal images of the decellularized scaffold is structurally 
complex and contains no cells (Figure 13A). 
The synchronicity of biopotential peaks in channels 1-8 indicates a degree of cell-cell 
interactivity (Figure 14). While channels 1-8 represent the biopotentials at 8 distinct locations 
across the construct, the peaks and troughs of the biopotential readings are relatively well matched. 
Variations in the biopotential amplitudes amongst electrodes may be due to minor variations in cell 
density at different locations around the BAH. Constructs were not paced prior to measurement, 
indicating the AHMs ability to self-pace. Furthermore, the spontaneous contractile frequency 
measured in Figure 14 is approximately 4.5 Hz, which is similar to the resting heart rate of a 
newborn rat. 
The methods described for generation of BAH constructs characterize an original protocol 
for establishing the framework of a tissue-engineered heart. Advanced tissue engineered heart 
muscle with a bioactive scaffold and high twitch force represents a novel vehicle for cellular 
delivery. A decellularized and highly structured scaffold allows potential for future sophistication 
and adaptability of the concept. Combination of the two allows for the inception of contractile and 
pumping ability to a structurally complex, natural heart scaffold. 
Static culture of tissue-engineered constructs is a limited technique and generally 
unsuitable for 3D tissue culture. True tissues in vivo are constantly subjected to a variety of stimuli, 
which direct the form and function of cells in the tissues. As such, it is essential to recreate some 
of the aspects of the in vivo environment in order to ensure enhanced performance and viability of 
tissue-engineered constructs (Chen and Hu 2006). Towards this end, we have begun work on 
several bioreactors for enhancing BAH function, including an electrical stimulation and a dual-
purpose perfusion bioreactor with the ability to perfuse media and provide mechanical stimulation 
simultaneously. While inclusion of AHM to the outer surface of the constructs is an efficient means 
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of cellular delivery, there was little cellular penetration into the decellularized scaffold. 
Recellularization of the decllularized matrix must occur in order to produce a more innate structure. 
The current model is formed using only 4 million cells per heart. Consequently, in order to improve 
construct similarity to native tissue, more cells must be added. One potential seeding method 
involves ε-aminocaproic acid. The acid is added during culture of the AHM to reduce degradation 
of the fibrin gel. If the acid is not added after construct formation, degradation of the gel occurs 
resulting in the deposition of a thin layer of cells to the outer surface of the decellularized matrix. 
If this process is repeated to embed multiple layers of AHM, it could represent an effective means 
of delivering a high number of cells to the construct. Another method for deposition of cells to the 
decellularized matrix involves direct injection. Unfortunately, direct injection is a relatively 
inefficient method with the majority of the cells washing out in culture. Pretreatment of cardiac 
myocytes with linker molecules or integrin stabilizers such as Manganese Chloride (MnCl2) may 
increase the efficiency of attachment of directly injected cells (Shimaoka, Takagi, and Springer 
2002; Grinnell 1984; McGinn et al., 2011). 
In this study, we describe a method establishing the framework for the formation of a 
bioartificial heart construct. Our use of sophisticated tissue engineered heart muscle along with a 
highly organized decellularized scaffold represents a promising advance towards the development 
of a true total bioartificial heart.  
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Chapter 4: Magnets and 3D Cultures 
Magnetic Cell Labeling and Levitation to Support the Rapid 
Assembly of Three-Dimensional Cardiac Cultures  
 Easily assembled organotypic co-cultures have long been sought in medical research. In 
vitro tissue constructs with faithful representation of in vivo tissue characteristics are highly 
desirable for screening and characteristic assessment of a variety of tissue types. Cardiac tissue 
analogs are particularly sought after due to the phenotypic degradation and difficulty of culture of 
primary cardiac myocytes. This study utilized magnetic nanoparticles and primary cardiac 
myocytes in order to levitate and culture multicellular cardiac aggregates (MCAs). Cells were 
isolated from 2 day old Sprague Dawley rat hearts and subsequently two groups were incubated 
with either C1: 33 µL NanoShuttle/million cells or C2: 50 µL NanoShuttle/million cells. Varying 
numbers of cells for each concentration were cultured in a magnetic field in a 24 well plate and 
observed over a period of 12 days. Constructs generally formed spherical structures. Constructs 
exhibited noticeable contraction after 4 days of culture and continued contracting past day 12 of 
culture. Phenotypic conservation of cardiac cells was ascertained using IHC staining by α-actinin, 
ki67, n-cadherin, cTnI and collagen. CD31 and fibrinogen were probed in order to confirm the 
presence of endothelial cells and levels of ECM production respectively. This study verifies a 
protocol for the use of magnetic levitation in order to rapidly assemble 3D cardiac cultures that 
preserve phenotypes and exhibit contractile activity.  
4.1 Introduction 
Three-dimensional (3D) cell culture systems represent an emerging and critical area of 
biomedical research. In recent years, the importance of a cost-effective, serviceable 3D culture 
system has become increasingly apparent (Zhang 2004; Haycock 2010; Griffith and Swartz 2006; 
Cukierman et al., 2001; Abbott 2003; Atala 2007; Pedersen and Swartz 2005). While two-
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dimensional (2D) cell culture experiments compose the primary mode of discovery since the 
inception of cell research, there are innate limits to flat culture. The gaps in complexity and fidelity 
between 2D cultures and native tissues, limit potential of research in 2D in vitro experiments. De-
differentiation, lack of multi-dimensional cell-cell connectivity, and structural simplicity contribute 
to the fundamental shortfalls of traditional culture models (Pampaloni, Reynaud, and Stelzer 2007). 
Organotypic culture systems, thus, have been a central area of concern in biomedical 
research for decades. Development of efficacious high throughput screening (HTS) methods for 
tissue-mimetic models represents a holy grail in the field (H. Zimmermann, Shirley, and 
Zimmermann 2007; Mueller-Klieser 1997; Mehta et al., 2012; Kwapiszewska et al., 2014; 
Takayama et al., 2013). Organotypic culture systems must meet several criteria in order to achieve 
prevalence. Simplified, cost-effective and consistent models retain greater potential for ubiquity 
than coordinately complex systems. A simple and effective model for 3D culture, which provides 
useful information on tissue response to chemical and physical environmental changes, is highly 
desirable. While pre-made scaffolds can be designed to mimic in vivo microenvironments, the 
extent to which this is possible is limited. Most scaffolds tend to limit the amount of cell-cell 
connectivity possible. This is particularly important when considering models involving cells like 
cardiac myocytes, which contain gap junctions that are essential to propagate action potentials. 
Scaffold free, spheroids have been found to have many desirable properties for drug screening 
purposes, and have compared favorably against more simplistic 2D screening models (Mehta et al., 
2012; Kwapiszewska et al., 2014; Takayama et al., 2013). 
Many forms of 3D tissue culture have been researched up to this point. Microfluidics based 
systems enjoy the advantages of a potential control of the microenvironment of systems along with 
a potential for improved sterility (Kwapiszewska et al., 2014; Wu, Huang, and Lee 2010). 
Unfortunately, procedural complexity and extensive equipment limit use of microfluidics HTS 
models in research. Rotational cell culture systems (RCCS) have the ability to spontaneously 
generate cell-dense 3D structures utilizing microgravity; however size and logistics are limiting 
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factors for HTS (Terai et al., 2002; Buckley, Thorpe, and Kelly 2009). Rapid generation of large 
numbers of individual 3D cultures can be logistically very difficult in rotating bioreactor systems. 
Further, altering the chemical characteristics of a large number of individual cultures 
simultaneously using RCCS presents a significant challenge. The limits of microgravitic forces on 
the surface of the Earth place a practical boundary on the size of tissue cultures generated using 
traditional rotating bioreactor culture methods. Scaffold based systems also have the ability to 
generate 3D architecture; however they are limited by material type/complexity and ability to truly 
mimic in vivo conditions (Asthana and Kisaalita 2013). Dr. Souza’s group have developed 
magnetic NanoShuttle which can be used to magnetically label and levitate cells in order to form a 
3D multicellular cardiac aggregate (MCA) (Haisler et al., 2013). A self-assembling model, 
requiring cells, one reagent and a magnetic source is not only a streamlined and simple model for 
the rapid generation of 3D organotypic tissues, it has also proven to be an effective model for 
preserving phenotype, functionality and viability of cells as well (Daquinag, Souza, and Kolonin 
2012; Tseng et al., 2013). Cardiac tissue analogs are particularly sought after due to the phenotypic 
degradation of primary cardiac myocytes in culture (Spahr et al., 1984; Coulombe et al., 2014; Hirt, 
Hansen, and Eschenhagen 2014). Cardiovascular drug development is one of the most important 
areas of pharmaceutical research with roughly 6 million people affected by heart disease in the 
United States (Go et al., 2013). The large market combined with the difficulty of culture of cardiac 
myocytes in a 2D environment make a 3D cardiac tissue culture model highly desirable. 
In vitro tissue constructs with faithful representation of in vivo tissue characteristics are 
highly desirable for screening and characteristic assessment of a variety of tissue types. This study 
established a method for the generation of 3D cardiac cultures through cellular coupling with and 
manipulation of ferromagnetic nanoparticles. 
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4.2 Materials and methods:  
All materials were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise 
specified. 
4.2.1 Ethics Statement 
All studies were performed in accordance with protocols approved by The Institutional 
Animal Care and Use Committee (IACUC) at the University of Houston (Protocol 11-040). 
Research was performed in compliance with the NIH Guide for Care and Use of Laboratory 
Animals.  
4.2.2 Isolation of primary cardiac cells 
Cardiac cells were isolated from the hearts of 2-3 day old neonatal Sprague-Dawley rats 
using an established method (L Khait and Birla 2007). Tissues were minced into 1 mm3 pieces and 
transferred to a dissociation solution (DS) consisting of filtered 0.32 mg/ml collagenase type 2 
(Worthington Biochemical Corporation, Lakewood, NJ) and 0.6 mg/ml pancreatin in phosphate 
buffer. A 50 mL conical tube containing 15 mL of DS and the minced tissues was placed in an 
orbital shaker and maintained at 37°C for 30 minutes at 60 rpm. At the end of the digestion process, 
the supernatant was collected in 3 ml of horse serum to neutralize the enzyme and centrifuged at 
1,000 rpm for 5 minutes at 4°C. The cell pellet was re-suspended in 5 ml horse serum and kept in 
an incubator at 37°C supplied with 5% CO2. Fresh DS was added to the partially digested tissue 
and the digestion process was repeated an additional 2-3 times. Cells from all the digests were 
pooled, centrifuged and suspended in culture medium (CM) consisting of M199 (Life 
Technologies, Grand Island, NY), with 20% F12k (Life Technologies), 10% fetal bovine serum, 
5% horse serum, 1% antibiotic-antimycotic, 40 ng/ml hydrocortisone and 100 ng/ml insulin. Cell 
concentration and viability was assessed by Trypan blue (4%) staining according to the 
manufacturer’s protocol. 
 
 52 
4.2.3 Magnetic Levitation 
Cells were converted to 3D cultures using the Bio-Assembler Kit (Nano3D Biosciences, 
Houston, TX). Two 50 mm tissue culture plates were coated with 3 ml of SYLGARD (PDMS, type 
184 silicone elastomer) (Dow Chemical Corporation, Midland, MI). The plates were air dried for 
2 weeks and sterilized with 80% ethanol before use. Magnetic levitation occurs through magnetic 
labeling with a nanoparticle assembly consisting of poly-L-lysine (PLL), magnetic iron oxide 
(MIO; Fe3O4, magnetite), and gold nanoparticles that self-assemble into networks based on 
electrostatic interactions (NanoShuttle; Nano3D Biosciences) (Hajitou et al., 2006; Arap, 
Pasqualini, and Ruoslahti 1998; Souza et al., 2006; Souza et al., 2008; Souza et al., 2010). Cells 
suspended in CM were plated on each petri dish and the nanoparticle assembly was added at 
concentrations of C1: 33 μL/106 cells or C2: 50 μL/106 cells. Cellular uptake of the biocompatible 
nanoparticles renders the cell magnetic, allowing for magnetic manipulation of cells; in particular, 
cells in a culture dish can be levitated to the air–liquid interface with the application of a low-
magnitude magnetic field (50–300G). The cell and nanoparticle suspensions were then incubated 
at 37oC for 30 minutes at 80 RPM. Nanoparticle loaded cell suspensions were subsequently 
centrifuged at 1000 rpm for 1 minute and the pellets were re-suspended to a concentration of 
2.5x106 cells/mL in CM. Nanoparticle treated cell suspensions were distributed in ultra lo-bind 24 
well culture plates (Corning Inc., Tewksbury, MA) at cell densities of 600,000, 300,000, 150,000 
and 75,000 cells with 400 μL of CM per well. Neodymium magnets with field strengths of 50 Gauss 
were immediately placed over each of the 24 wells of the culture plate to levitate the cells to the 
air-liquid interface (Figure 15). 
 53 
 
Figure 15: Schematic of magnetic levitation in a 24-well plate, A, Cells are isolated, B, E,  
                   magnetically labeled with NanoShuttle, C, distributed within a 24-well plate , D, F, 
                   a magnet is applied, G, The levitated cells compact and form a cell dense MCA. 
 
4.2.4 3D Culture Formation and Activity 
 Levitated 3D cultures were examined daily to examine contractile action and gross 
morphology using an inverted phase-contrast microscope (Nikon Instruments Inc., Melville, NY). 
Still photographs and videos were captured daily and examined using NIS elements software 
(Nikon Instruments Inc., Melville, NY) (Figure 16). MCAs were picked up and placed as necessary 
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during culture using a Teflon coated magnetic pen. MCAs were held along the bottom of the 24 
well plates with a magnet during media changes. Fresh media was added every other day. 
4.2.5 Histology and Immunohistochemistry 
For whole mount immunohistochemistry (IHC), each sample was lifted from the 24 well 
culture plate and placed in a 96-well plate using a Teflon coated magnetic pen. A magnet was 
applied to the bottom surface of the 96-well plate to hold the samples in place. Samples were rinsed 
with PBS, fixed in 10% NBF for 10 minutes, rinsed again, permeabilized with 0.5% Triton X-100 
in PBS followed by a final wash in PBS. Cross-sections were obtained by freezing samples in OCT 
and sectioning them with a cryotome (Thermo Fisher Scientific, Waltham, MA). Cross-sections 
were fixed in ice-cold acetone for 10 minutes. Depth-specific cross-sections of entire particles were 
obtained at regular intervals for several samples. Nonspecific epitope antigens were blocked with 
10% goat serum at room temperature for 1 hour for cross-sections and whole mount samples. 
Samples were incubated with some combination of mouse anti-α-actinin monoclonal antibody 
(Sigma, A7811) 1:200 with polyclonal rabbit anti-collagen type I (Abcam, ab34710) 1:100, 
polyclonal rabbit anti-CD31 (Abbiotec, 250590) 1:100, polyclonal rabbit anti-fibronectin 
(Abbiotec, 252234) 1:80, polyclonal rabbit anti cTnI (Abcam, ab47003) 1:100, polyclonal rabbit 
anti-ki67 (Abcam, ab15580) 1:100 or polyclonal rabbit anti-n-Cadherin (Abcam, ab12221) at room 
temperature for 1 hour. α-actinin presence was attributed to cardiac myocytes. CD31 was assessed 
in order to ascertain the localization and abundance of endothelial cells. Fibronectin was similarly 
observed for ECM robustness (Figure 17). Cardiac troponin I is a cardiac specific marker associated 
actin and tropomyosin and is part of a complex which confers calcium sensitivity to striated muscle. 
Further, ki67, a protein associated with cell division and n-cadherin, a transmembrane protein 
associated with adherens junctions were similarly probed to visualize associated structures. 
Subsequently, samples were treated with goat anti-mouse and goat anti-rabbit secondary antibodies 
(Alexa Fluor 488 and Alexa Fluor 546, Life Technologies, Grand Island, NY) 1:400 at room 
temperature for 1 hour. Nuclei were counterstained with 4, 6-diamidino-2-phenylindole (DAPI) 
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(2.5 μg/ml) for 5 min at room temperature. Fluorescent images were obtained with a Nikon C2+ 
confocal laser-scanning microscope (Nikon Instruments Inc., Melville, NY). Z-stack images were 
taken in order to examine 3D structures of the samples. Masson’s trichrome stains were performed 
on interval sections of an MCA and observed under a light microscope. 
4.3 Results 
4.3.1 Formation 
 Formation of the MCAs was 
reproducible for all cell densities used 
throughout our trials. The process was 
repeated n=10 times for a total of 240 
MCAs formed with a variety of cell 
concentrations. Addition of the 
particles tended to cause clumping 
during the incubation phase. Simple 
agitation was sufficient to disrupt these 
transient interactions and re-disperse 
the cells in the medium. Upon 
application of the magnet, the cells 
moved to the air-liquid interface. By 
day 2, a centralized aggregate began to 
form. Within 4 days most cells were incorporated into the central aggregate with few remaining 
satellite structures (Figure 16). There was little difference between the size and structure of 3D 
constructs generated using either C1 or C2 concentrations of NanoShuttle. Constructs were 
generally stable in geometry and mostly remained intact through 12 days of culture. Satellite 
 
Figure 16: MCA aggregate formations over time, A,  
                   C1: 33 µL particle/million cells, B, C2: 50  
                   µL particle/million cells. 
 56 
structures tended to merge with larger 
structures and compact slightly over 
time. MCAs were easily moved and 
manipulated using the Teflon-coated 
magnetic pen. 
4.3.2 Activity 
 MCA contractions were 
observable beginning at day 3 or 4 and 
were visible by spontaneous 
deformation, rotation, and translation. 
Contraction was clearly observable in 
75% (n=24) of MCAs. Higher cell 
densities may correlate to a higher 
degree of observable contraction given 
that in one study MCAs with a density of 
300,000 cells per well contracted 
observably 83.3% (n=12) of the time 
while those with a density of 150,000 cells per well contracted observably 66.7% (n=12) of the 
time. 
4.3.3 Histology and immunohistochemistry 
  Immunohistological staining of whole-mount preparations confirmed a spherical 
architecture of the MCAs (Figure 18). Three-dimensional images of MCAs probed for α-actinin 
and collagen illuminate the periphery of the spherical constructs. Interior portions were not visible 
in deeper z-slices of the stained preparations. Sections of an MCA at regular 100 m intervals 
revealed cell-dense structures with pronounced collagen networks (Figure 19). Interior portions 
 
Figure 17: IHC images of whole-mount MCAs  
                   probed for α-actinin (green) and either  
                   collagen, CD31 or fibronectin (red). 
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were positive for α-actinin and DAPI stains confirmed cell-presence throughout. Z-band α-actinin 
formations can be seen, however alignment and fiber lengths are lower than in native tissues (Figure 
20B). MCAs probed for CD31 and Fibronectin illustrated protein presence under whole-mount 
preparations. MCAs probed for cTnI indicated troponin I presence along muscle fibers (Figure 
20A, B). Probes for ki67 illustrate that MCAs were positive for cellular division, and n-cadherin 
probes indicate moderate expression of the proteins at 12 days (Figure 20C, D). 
 
Figure 18:  Z-stack 3D reconstruction of IHC images from whole-mount MCA, Probed for α- 
                   actinin (green) and collagen (yellow). 
 
4.4 Discussion 
 The technique presented in this paper was used to successfully generate hundreds of MCAs 
with relative ease. The MCAs presented with similar geometry and formed with a 100% success 
rate. The ease with which this technique was applied to generate 3D cardiac structures using 
primary cardiac myocytes makes it an attractive multidimensional culture technique. MCA size 
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manifested in approximate proportion to the number of cells used up to 600,000 cells, indicating a 
rough ability to control MCA size in culture. The amounts of nanoparticle added to the cells prior 
to levitation (C1 and C2) were proscribed based on previously successful magnetic nanoparticle 
concentrations for levitation of other cell types and results of preliminary studies (Tseng et al., 
2013). An estimated 1 μL per 10,000 cells had previously been used to successfully levitate other 
cell types, however it was apparent that less particle could be used when incubating cardiac cells 
with the protocol described herein. Given that there was no discernable difference between 
formation time and size of C1 and C2 treated MCAs, it is conceivable that even less magnetic 
nanoparticle could be used. All studies were performed using a 24 well culture plate, however the 
technology could conceivably be scaled up to a 96 well system in order to increase throughput. 
 Most MCAs were observed to contract visibly under the light microscope; however, it was 
difficult to visibly ascertain contractile frequency due to the small size of the particles and 
variability of the motion caused by contraction. The visible contractility serves as an obvious 
indicator of cardiac myocyte presence and phenotypic stability. It was observed that MCAs formed 
with higher concentrations of cells contracted more visibly under a light microscope. It may be that 
higher concentrations of cells allow for greater cardiac myocyte coordination and action; however 
the inherent uncertainty of qualitative assessment prohibits any conclusive analysis. Smaller MCA 
contraction may be present in proportionally similar amounts to those of larger MCAs. Given that 
there are less cells generating contractile action in smaller MCAs, the overall stabilizing force of 
the magnetic field and air-liquid interface may overcome the net contractile action of the cardiac 
myocytes. A more reliable and quantifiable method of functional detection is necessary for further 
analysis of MCA capabilities. Given the small size of the MCAs, functional extraction is not as 
straightforward as with larger tissue constructs. EKG, twitch force and calcium transient data 
extraction, remain non-trivial challenges which can be addressed to improve the significance of 
this model.  
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 Whole mount confocal assessment of the MCAs revealed -actinin, collagen, CD31, 
fibronectin, ki67, cTnI and n-cadherin presence (Figures 17-20). Three-dimensional images of 
whole mount sections revealed interconnected collagen networks around the perimeter of the 
MCAs (Figure 18). Interior portions of the MCAs were not visible using this method due to light 
scattering. In order to confirm cellular presence and activity of interior portions, interval cross-
sections of an MCA were probed for collagen and α-actinin (Figure 19).  
 
Figure 19: Cell dense structures, IHC images of cross sections of MCA sectioned at discrete  
                   depths probed for α-actinin (green) and collagen (yellow) and the corresponding  
                   bright-field image of the MCA prior to sectioning.  
 
Interior sections revealed cellular presence and were positive for both collagen and α-
actinin throughout the interior of the MCAs. Furthermore, given that the confocal analysis was 
performed after 12 days of culture, positive stains for fibronectin and collagen, CD31, and α-actinin 
indicate the relative phenotypic stability of fibroblasts, endothelial cells and SM cardiac myocytes 
and a similarity of cellular composition of the MCAs to cardiac smooth muscle after a moderate 
period of culture. Given that cardiac myocytes tend to de-differentiate immediately in 2D culture, 
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phenotypic stability is invaluable for in vitro testing (Spahr et al., 1984). The presence of ki67 
suggests maintenance of active cell division within levitated MCAs (Figure 20C). Z-band striations 
indicate some degree of phenotypic preservation of muscle fiber structure (Figure 20B). However, 
the lack of alignment and reduced length of muscle fibers visualized by distinct z-bands indicates 
a limit to the structural similarity of MCAs to heart muscle tissue. Further, while n-cadherin 
presence is indicative of adherens junctions, the organization does not indicate tissue level 
organization of the structures (Figure 20D). Still, three dimensional geometry allows for an 
increased n-cadherin presence through interlayer connectivity between cells in MCAs when 
compared to monolayers. Moreover, cellular organization strategies, electrical stimulation, 
perfusion and magnetic mechanical stimulus can all potentially be incorporated into the system in 
order to improve structural and phenotypic resemblance of MCAs to native tissues. 
 
Figure 20: Structural Preservation, MCAs were probed for α-actinin (green) and DAPI (blue).  
                   MCAs were secondarily probed for (red), A, B, cardiac troponin 1, C, ki67 and, D,  
                   n-cadherin. 
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 Each experiment was performed using a 24 well plate. Individual wells in the plate can be 
prepared with a different chemical or physical stimulus allowing for an increased throughput when 
compared to rotational bioreactor systems. What is more, the form factor of the equipment is 
reduced when compared to RCCS strategies. The entire 24 well system measures 5” L x 3.3” W x 
1.1” H. Furthermore, scalability is a simple matter as 96 well plates can easily be prepared to 
implement the same formation strategy. 
4.5 Summary 
 MCAs generated using the methods described above clearly generated 3D cell dense 
aggregates. The inter-dimensional cell-cell activity conferred not only a degree of phenotypic 
stability, but also allowed for continued functionality of the active cell types in cardiac muscle. 
Given the ease with which MCAs were generated and the similarity to heart muscle, the described 
technology presents an intriguing potential for high-throughput screening of cardiac muscle 
analogs.  
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Section 2: Bioreactors for Conditioning of 
Cardiovascular Tissue Models 
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Chapter 5: Magnetic Stretch Conditioning 
Field Manipulation for Non-Contact Magnetic Stretch 
Conditioning of Cardiovascular Tissue Models 
 Bioreactor systems have become an integral component of tissue engineering methods. 
Cardiovascular stretch conditioning systems have a wide array of beneficial effects for maintenance 
and enhancements of in vitro tissue engineered cardiac muscle systems; however a high degree of 
axial control, enclosed environments to enhance sterility and diffused loading are difficult to 
achieve in a contact based system. We endeavored to apply magnetically induced stretch 
conditioning through application of an oscillating magnetic field to a ferromagnetic heart muscle 
model. Fibrin scaffolds were loaded with magnetic particles prior to tissue model formation. 
Oscillating magnetic fields were applied by a novel bioreactor system through displacement of a 
neodymium magnet. Addition of Iron (III) Oxide (Fe2O3) in sufficient quantities to allow for 
physiologically relevant stretch (15% axial displacement) caused toxic effects after 4 days of 
culture. Loading scaffolds with magnetite (Fe3O4) nanoparticles in tight size distributions increased 
the field strength of magnetized fibrin 10 fold over Fe2O3 with disperse distributions. Loading with 
Fe3O4 allowed for relevant stretch and negligible toxicity within 8 days of culture.  
5.1 Introduction 
5.1.1 Motivation 
Heart failure is a leading cause of death worldwide and there remains an unprecedented 
need to develop novel treatment strategies. Tissue engineering is an investigational strategy being 
developed to support lost myocardial function, focused on fabrication of artificial tissue that can be 
used as a therapeutic strategy for myocardial infarction. The principle of heart muscle tissue 
engineering is to culture isolated cells within complex 3D matrices, resulting in fabrication of 3D 
artificial heart muscle (3D-AHM). Subsequently, 3D-AHM is conditioned using stretch bioreactors 
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to support alignment of cells. Stretch is an important modulator of heart muscle function and several 
groups, including work from the PI’s lab, have demonstrated a positive correlation between stretch 
and 3D-AHM function. However, all stretch bioreactors are contact-based and lead to physical 
tissue damage and limit functional benefit. In order to address this, we propose to engineer a novel 
non-contact magnetic stretch bioreactor (MSB) to support functional improvement of 3D-AHM.  
5.1.2 Viable Tissue Engineered Heart Muscle 
Heart disease is one of the most important medical concerns in this country and is the 
leading cause of death in the United States. Over 3 million people live with heart disease in the 
United States. Managing these patients accrues costs of nearly 25 billion per year. Given that 
cardiac muscle tissue has very limited regenerative capabilities, a viable tissue engineered muscle 
replacement/supplement to augment contractile function may serve as a bridge or even alternative 
treatment to heart transplant. Furthermore, successful generation of a physiologically relevant 
tissue engineered heart muscle will be an important first step in the creation of a true tissue 
engineered whole heart. Three-dimensional tissues also hold relevance in the field of drug 
screening and tissue response in vitro. 
5.1.3 Current Models 
Tissue engineering strategies are focused on the fabrication of artificial tissue constructs in 
a controlled laboratory environment. (Atala 2004; Luda Khait et al. 2008) The definition of tissue 
engineering was provided by Dr. Robert Langer in one of his seminal papers, where he states that 
“Tissue engineering is an interdisciplinary field that applies the principles of engineering and the 
life sciences toward the development of biological substitutes that restore, maintain, or improve 
tissue function” (Langer and Vacanti 1993). This seminal publication has been influential in the 
field and has resulted in an exponential increase in research participation. Advances in tissue and 
organ fabrication technology have led to clinical implantation of bioengineered tracheas and 
bladders and organ model have been developed for artificial hearts, lungs and kidneys.   
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The most common strategy to fabricate 3D-AHM has been to culture neonatal cardiac 
myocytes within a suitable 3D scaffold, resulting in artificial tissue that replicates a partial subset 
of mammalian heart muscle function. Three pillars of heart muscle tissue engineering have evolved: 
cells, biomaterials and bioreactors (Chiu et al., 2011; Hecker and Birla 2007; Eschenhagen et al., 
1997). 
 Cells – cells provide the functional component of 3D artificial tissue and most models of 
artificial heart muscle have been developed using neonatal cardiac myocytes. While 
artificial tissue fabricated using neonatal cells cannot be used clinically, these models 
provide valuable insight into 3D organization and development.     
 Biomaterials – many biomaterials have been tested to support artificial heart muscle, 
including fibrin, collagen, alginate, chitosan and polyglycolic acid (Williams et al., 2014; 
H.-J. Wei et al., 2006; H. Zimmermann, Shirley, and Zimmermann 2007; Feng et al., 2008; 
Pok et al., 2014). These materials have demonstrated varying degrees of success and 
replicated partial functionality of artificial heart muscle.      
 Bioreactors – bioreactors are used to replicate in vivo conditions during controlled in vitro 
culture; specific signals include mechanical stretch, electrical stimulation and fluid stress 
(Maidhof et al., 2008; Boonen et al., 2010; Gwak et al., 2008; Au et al., 2009). These 
signals are important in guiding the formation and function.   
5.1.4 Effects of Stretch Conditioning 
There have been several studies describing the fabrication of artificial heart muscle, 
including publications from our lab (Luda Khait and Birla 2008; Hogan et al., 2014; Y.-C. Huang, 
Khait, and Birla 2007). These studies have often been coupled with studies designed to evaluate 
the role of physiological stimulation (mechanical stretch, electrical stimulation, and perfusion) to 
guide 3D tissue formation/function. Our group has developed several models of 3D heart muscle, 
and one of the models developed by our group, the 3D-AHM, is based on the spontaneous 
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delamination of a monolayer of primary neonatal cardiac cells that are distributed within a fibrin 
gel network (described in the preliminary data). Cardiac cells are plated on a tissue culture surface 
that has been coated with a layer of fibrin gel. Spontaneous contractions of the cell monolayer lead 
to compaction of the fibrin gel, resulting in formation of functional 3D artificial heart muscle. 3D-
AHM can be electrically stimulated to generate twitch forces of over 4 mM and can also be 
electrically paced at frequencies of 1-7 Hz without fatigue. 
Under normal physiological conditions, the heart responds to changes in hemodynamic 
loads by increases in extracellular matrix components in addition to hypertrophic and hyperplasic 
growth of the cardiac cells. Under normal physiological conditions, pressure overload in the heart 
leads to an increase in the rate of proliferation of cardiac fibroblasts associated with an increase in 
expression of collagen type I. Changes in hemodynamic loading resulting from volume overload 
are also associated with cardiac myocyte hypertrophy, in addition to increases in collagen 
deposition. A significant amount of information has been obtained about the changes in phenotype 
of cardiac myocytes and fibroblasts in response to mechanical stretch using in vitro models. In 
addition to validating the increase in collagen production and rate of proliferation of cardiac 
fibroblasts, there is growing evidence to suggest that several growth factors (TGF-β, PDGF, b-
FGF, IGF-1, AngII, ET-1) may play a pivotal role in mediating the response of cardiac fibroblasts 
to mechanical stretch. The current data suggest that hemodynamic overload initiates a cellular 
response, which is further modulated by changes in growth factor environment through an autocrine 
loop. Myocardial stretch promotes a release of Ang II that induces the release/formation of 
endothelin (ET) through the activation of the AT1 receptors, which in turn, and acting in an 
autocrine/paracrine fashion, activates the cardiac Na+/H+ exchanger (NHE-1). The increase in 
intracellular Na+ concentration ([Na+]i), mediated by this NHE-1 activation, but not the change in 
pHi, drives the Na+/Ca2+ exchanger (NCX) in reverse mode, increasing Ca2+ transient (Ca2+T) and 
contractility. 
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5.1.5 Bioreactors: Current State of the Art 
There have been several studies which describe a positive correlation between stretch and 
heart muscle function (Ku et al., 2006; Balachandran Philippe Jo, Hanjoong Yoganathan, Ajit P. 
2009; Aida Salameh, Wustmann, et al., 2010; Riehl and Park 2012; Boonen et al., 2010). Fink et al 
utilized a mechanical stretch regime to study changes in 3-dimensional cardiac muscle that was 
engineered by culturing neonatal cardiac cells within a collagen gel (Fink et al., 2000). The 
constructs were subjected to a 20% stretch protocol at a frequency of 1.5 Hz for a period of 6 days; 
this resulted in doubling of the twitch force. In addition, mechanical stretch resulted in an increase 
in calcium sensitivity and an increase in the β-adrenergic response (Aida Salameh, Karl, et al., 
2010). Akyhari utilized a model of 3-dimensional heart muscle by culturing cells obtained from 
human hearts and culturing the cells in a gelatin sponge. The constructs were subjected to a protocol 
of 20% stretch at a frequency of 1.33 Hz for a period of 14 days. Although the contractile properties 
were not evaluated, stretch did result in an increase in cell proliferation (Akhyari et al., 2002). 
5.1.6 Novel Stretch Bioreactors 
In the previous section, we looked at a few examples of stretch bioreactors and the effect 
of controlled stretch on artificial heart muscle function. In all cases, stretch bioreactors have been 
custom fabricated by the lab; all stretch bioreactors till date require physical contact with artificial 
heart muscle. We believe that physical contact with tissue results in physical damage and loss of 
function. The current study is designed to address this limitation and fabricate a non-contact MSB. 
We believe that non-contact stretch bioreactors will lead to greater degree of functional 
improvement, when compared with stretch bioreactors.  
During preliminary studies, we used magnetic fields for controlled stretch of 3D-AHM. In 
order to achieve this objective, we first developed a novel method to engineer 3D-AHM using 
iron(III) oxide particles; this resulted in magnetized 3D-AHM, termed m3D-AHM. Our second 
objective was to use controlled magnetic fields for stretch conditioning of m3D-AHM. During 
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preliminary studies, we successfully fabricated two generations of non-contact MSBs. To the best 
of our knowledge, this work was the first demonstration of magnetic fields used non-contact stretch 
of 3D heart muscle. The purpose of this study is to build upon this foundation and develop a new 
generation of MSBs, optimize culture conditions to support fabrication of m3D-AHM and couple 
these two technologies and guide m3D-AHM development using non-contact MSBs. We propose 
to build a new MSB to condition m3D-AHMs that have been fabricated using optimized culture 
conditions; we hypothesize that non-contact MSBs will provide significant functional 
enhancement, greater that obtained using contact based stretch bioreactors. 
This work will provide technology for controlled non-contact mechanical stretch to condition 
3D-AHM; this work can also be extended to other tissue systems. Successful completion of the 
proposed study will lead to the development of novel non-contact based technology for tissue 
engineering bioreactors; this will be a significant advancement based on current state of the art in 
the field.  
5.2 Materials and Methods 
All animal protocols were approved by the Institutional Animal Care and Use Committee 
(IACUC) at the University of Houston, in accordance with the Guide for the Care and Use of 
Laboratory Animals (NIH Publication No. 86–23, 1996). All materials were purchased from Sigma-
Aldrich (St. Louis, MO, USA) unless otherwise specified. The chemicals used in the syntheses 
and characterization were of analytical grade and were used as received from the supplier 
without further purification. Millipore water (resistivity of >18 MΩ-cm) from a Milli-Q 
water system and filtered through a 0.22 μm filter membrane was used in the synthesis and 
washing steps. All glassware and equipment were cleaned in an aqua regia solution and rinsed 
with Milli-Q water prior to use. 
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5.2.1 Isolation of primary cardiac cells 
Cardiac cells were isolated from the hearts of 2–3 day-old neonatal Sprague–Dawley 
rat pups, using an established method. (Y.-C. Huang, Khait, and Birla 2007) Each heart was 
cut into three or four pieces in an ice-cold phosphate buffer consisting of 116 mM NaCl, 
20 mM HEPES, 1 mM Na2HPO4, 5.5 mM glucose, 5.4 mM KCl and 0.8 mM MgSO4. 
After the blood cells had been rinsed out, the heart pieces were transferred to a dissociation 
solution consisting of 0.32 mg/ml collagenase type 2-filtered (Worthington Biochemical 
Corporation, Lakewood, NJ, USA) and 0.6 mg/ml pancreatin in phosphate buffer. The hearts 
were cut into 1 mm3 pieces and then transferred to an orbital shaker and maintained at 
37°C for 30 min at 60 rpm. At the end of the digestion process, the supernatant was collected 
in 3 ml horse serum to neutralize the enzyme and centrifuged at 1000 rpm for 5 min at 
4°C. The cell pellet was re-suspended in 5 ml horse serum and kept in an incubator at 
37°C, supplied with 5% CO2. Fresh dissociation solution was added to the partially 
digested tissue and the digestion process was repeated a further two or three times. Cells 
from all the digests were pooled, centrifuged and suspended in culture medium (CM) 
consisting of M199 (Life Technologies, Grand Island, NY, USA) with 20% F12k (Life 
Technologies), 10% fetal bovine serum, 5% horse serum, 1% antibiotic–antimycotic, 40 ng/ml 
hydrocortisone and 100 ng/ml insulin. Cell viability was analyzed by Trypan blue (4%) 
staining, according to the manufacturer’s protocol. 
5.2.2 Fabrication of artificial cardiac patch 
A 35 mm tissue culture plate was coated with 2 ml SYLGARD (PDMS, type 184 
silicone elastomer; Dow Chemical, Midland, MI, USA). The plate was air- dried for 2 
weeks and sterilized with 80% ethanol before use. Four minutien pins (Fine Science Tools, 
Foster City, CA, USA), 0.1 mm diameter, were placed in the culture plate to form a 2 × 2 
cm square. The fibrin gel was made by plating 1 ml CM containing 10 U/ml thrombin, 
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adding 500 μl saline containing 20 mg/ml fibrinogen and mixing well to promote gel 
formation within 10 min. Primary cardiac cells were diluted in CM at a pre-set density, and 
2 ml of the cell suspension was transferred to the culture plate. Aminocaproic acid (2 mg/ml) 
was added to the culture plate to inhibit fibrinolysis by endogenous proteases. The cells were 
cultured in an incubator at 37°C and 5% CO2 with CM changes every other day. 
5.2.3 Magnetized fibrin gel 
Magnetized fibrin scaffolds were formed and seeded the same way as their un-
magnetized counterparts. Fe203 particles (Sigma Aldrich) with diameters <5 m were added 
to the fibrinogen in saline and thrombin in CM mixture immediately after combination of the 
CM and saline in a PDMS coated petri dish. Fe203 was added by weight % in increments of 2 
wt% with groups of 1, 3, 5, 7, 9, 11 and 13 wt% corresponding to 15, 45, 75, 105, 120 and 135 
mg respectively. Cells were added to the magnetized fibrin gel in the same manner as with un-
magnetized matrices. Magnetized fibrin gels were also formed using well characterized 
magnetite (Fe3O4) nanoparticles of 100nm and 300 nm diameters. Particles were sonicated in 
CM and mixed with fibrinogen in saline and thrombin in CM.  
5.2.4 Patch formation and contraction rate 
Sixteen hours after cell plating, spontaneously beating cardiomyocytes were counted 
manually from five ×200 fields (center and top, right, left and bottom-most from the center 
of the patch) under an inverted phase-contrast microscope (Olympus, Centre Valley, PA, 
USA). The contraction of cultured cardiac constructs and fibrin gel detachment from culture 
plates were observed from day 1 to day 6; the patch growth progress was captured in still 
photographs and videos, using a camera (Lumenera, Ottawa, ON) mounted on an inverted 
phase-contrast microscope. The videos were replayed slowly and the contraction rates 
manually counted. 
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5.2.5 Contractile twitch force and electrocardiogram (ECG) 
From the first day of patch formation, spontaneous and electrical paced twitch force (10 
V, 0.1 s) were measured within a thermostatic (37°C) water bath using a high-sensitivity 
isometric force transducer (MLT0202, ADInstruments, Colorado Springs, CO, USA) 
connected to a quad bridge amplifier (FE224, ADInstruments). ECG signal was measured 
using Octal Bio Amp (ML138, ADInstruments). Data were acquired through a 16-channel 
PowerLab system (PL3516/P, ADInstruments). The contractile twitch force was measured 
by attaching the force transducer arm to one free-corner of the square patch, while the other 
three ends of the square patch were held fixed by pins. In order to obtain the Frank– Starling 
relationship for the measured twitch force, pretension was adjusted using a micro-manipulator 
(Radnoti LLC, Monrovia, CA, USA) and measurements of spontaneous contraction were 
recorded. We defined a spontaneous con- traction rate of > 120 bpm as high-rate contraction 
and a spontaneous contraction rate of < 20 bpm as low-rate con- traction. The ECG of the 
patch was measured by inserting a needle cathode (MLA1213, ADInstruments) into the 
centrer of the patch and a needle anode in one of the four patch corners. The medium 
immersing the patch was used as ground. LabChart (ADInstruments) was used for data 
analysis. The peak analysis module was used to calculate the maximal twitch force and baseline 
force (pre-tension). The ECG analysis module was used to calculate the R-wave amplitude. 
Electrical pacing was performed by attaching the stimulating electrodes (MLA0320, 
ADInstruments) on the edge of the patch tissue at frequencies of 0.25, 0.5 and 1–8 Hz (in 
1 unit increments) at 2, 4 and 6 days after patch formation. 
5.2.6 Morphology 
Seven days after plating, the formed patches were cut diagonally. The diagonal 
edge of the triangular block was aligned with the edge of a slide. The cross-section and 
surface of the triangular block were photographed and the images were traced using 
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ImageJ 1.47d (Wayne Rashand, National Institutes of Health, USA) to obtain the area 
of the cross-section, the thickness and the height of the triangular block, and then this 
triangular block was weighed. From the central part of the patch, two 0.5 × 0.5 cm blocks 
were taken, placed in a peel-away disposable embedding mold (VWR International, Radnor, 
PA, USA), frozen in liquid N2 and then immediately immersed in Tissue Tek OCT compound 
(VWR International, Radnor, PA, USA) and placed in a -80°C freezer. Once the OCT 
compound solidified, each sample was sliced using a cryostat (Thermo Fisher Scientific, 
Waltham, MA, USA). Tissue cross-sections and planar sections were cut at a thick- ness of 10 
or 6 μm. The sections were placed on VWR® Microslides for preparation of morphological 
and immunofluorescence examinations. Images from cross-sections of 6 μm thickness were 
taken directly under a phase-contrast light microscope (Olympus, Centre Valley, PA, USA). 
For measurement of the ‘real cardiac layer’ (a layer of cells and naturally produced extracellular 
matrix forming on top of the fibrin gel scaffold) thickness, 10 μm thick cross-sections were 
stained with Masson’s trichrome, according to the manufacturer’s protocol, and images were 
taken under a light microscope. The distinct tissue layers were traced and thicknesses calculated 
using ImageJ. 
5.2.7 Immunofluorescence 
For observation of endothelial cell growth, nuclear division and collagen type I 
distribution in the patch, fresh tissue patches were directly fixed in ice-cold acetone for 10 
min; 1.0 × 1.0 cm tissue patch blocks from the center were trimmed, non-specific epitope 
antigens were blocked and the cell membranes permeated with 10% goat serum/ 0.5% Triton 
X-100 at room temperature for 45 min. Tissue patch blocks were then incubated in mouse 
anti-α-actinin antibody (1:200; Sigma, A7811), rabbit anti-collagen type I (1:100; Abcam, 
ab34710), rabbit anti-von Willebrand factor (vWF; 1:750; Abcam, ab6994), rabbit anti-ki 
67 (1:100; Abcam, ab66155) or rabbit anti-connexin 43 (Cx43; 1:100) at room temperature 
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for 2 h. Subsequently, tissue blocks were treated with goat anti-mouse and goat anti-rabbit 
secondary antibodies (1:400; AlexaFluor 488, 546 and 633, Life Technologies) at room 
temperature for 1 h. Nuclei were counterstained with 4,6-diamidino- 2-phenylindole (DAPI; 
2.5 μg/ml) for 5 min at room temperature. Fluorescent images were obtained using a Nikon 
C2+ confocal laser-scanning microscope (Nikon Instruments, Melville, NY, USA). For 
measurement of the volume indices of gap junctions, collagen fibers and myofibrils, signal 
volumes of Cx43, collagen type I and α-actinin expressions were examined within 6 μm 
cross- sections. Two Z-stack scans from each sample were acquired, with a signal depth 
of 8 μm over 33 frames. After determining specific thresholds for Cx43, collagen type I 
and α-actinin, signal volumes for each sample were measured.  
5.2.8 Statistics 
Results are presented as mean ± standard deviation (SD). χ2 analysis was used to 
test frequency variables. Comparisons among groups were made with a one-way analysis 
of variance (ANOVA) followed by the Bonferroni post hoc comparison test. In all tests, 
differences were considered statistically significant at p < 0.05. 
5.2.9 Magnetic conditioning 
Magnetized AHM was placed on a stage and held in place using metal clamps. A 
neodymium magnet was physically displaced relative to the m-AHM using a stepper motor 
driven ball-screw. The rate, distance and ramp speed of the oscillation was controlled through 
a custom user interface using a C2000 microcontroller (Texas Instruments, Austin, TX, USA) 
to drive the stepper motor. Code Composer Studios (CCS) was used to develop the UI, encode 
the microcontroller and display real-time feedback. 
5.2.10 Synthesis of Fe3O4 Magnetic Nanoparticles (MNPs) 
The Fe3O4 MNPs were synthesized by a modification of a procedure reported by Deng et 
al (Deng et al., 2005). In this modified procedure, a 150ml round-bottomed flask pressure vessel 
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was charged with FeCl3.6H2O (4.2 g) in 30 mL of ethylene glycol followed by the addition of 
sodium acetate (3.08 g). The latter addition leads to a rapid change in the color of the solution from 
orange to brown. The solution was then stirred for 30 min followed by the addition of polyethylene 
glycol (0.50 g) with 20 mL of ethylene glycol. The flask was sealed by a Teflon cap and heated at 
188°C for 21 hours. The black precipitate obtained was separated using a strong bar magnet and 
washed with three cycles each of ethanol and water and then dispersed in ethanol. The synthesized 
particles formed a powder upon drying at 40 °C and were set aside for future use. The concentration 
of starting materials and diethylene glycol was varied to obtain MNPs with varying sizes (Xuan et 
al., 2009). 
5.2.11 Characterization of MNPs 
The MNPs were characterized by scanning electron microscopy (SEM; LEO-1525 
operating at 15 kV) and vibrating sample magnetometry (VSM; LakeShore VSM 7300 Series with 
LakeShore 735 Controller and LakeShore 450 Gaussmeter Software Version 3.8.0). To obtain high 
resolution SEM images, all samples were deposited on a silicon wafer. The magnetic properties 
(saturation magnetization and coercivity) were measured by VSM with known mass. 
5.2.12 SEM Sample Preparation for MNPs in Fibrin Gel 
The MNP-scaffold samples were imaged using SEM (LEO-1525 operating at 15 kV). Prior 
to imaging, we prepared our samples based on the procedure of fixation, dehydration and drying 
methods (Khantamat et al., 2015). The fibrin scaffolds with MNPs were fixed with 2.5% (v/w) 
glutaraldehyde for 20 h in 0.1M PBS buffer at 4OC. The fibrin samples dehydrated in a gradient 
ethanol series (50%, 70%, 85%, 95%, and 100%) for 10 min each. The dehydrated samples were 
immersed and frozen in 100% t-butanol and followed by freeze-drying using a Scanvac CoolSafe 
110-4 (LaboGene). The freeze-dried samples were then sputter-coated (Hummer 6.2 Sputter 
System; Anatech USA) with a resultant thickness of about 10 nm platinum and then examined 
under SEM. 
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5.3 Results 
5.3.1 Concept 
Initial analysis of magnetic scaffolds was performed on fibrin gels containing 
uncharacterized Fe2O3. The process for magnetization and deformation of fibrin gels can be 
seen in Figure 21. Upon loading with Fe2O3, the fibrin gels became sensitive to magnetic fields. 
Higher initial loads of Fe2O3 resulted in effluent particles, which were not retained in the fibrin 
gel. The excess particle indicates that there is a threshold for loading of Fe2O3 in fibrin gel. 
The unloaded Fe2O3 became significant when attempting to form higher than 13 wt% Fe2O3 
magnetized fibrin scaffolds placing an upper limit on efficient magnetic particle loading. 
Stretch was found to positively correlate with magnetic field strength, which is inversely 
related to neodymium magnet distance from the culture chamber.  
5.3.2 Bioreactor Design 
Ideally, the system would be able to rapidly adjust magnetic field strengths so as to 
reproduce native contraction speeds and to allow for the greatest degree in variability of control. 
Ultimately we would like the translation distance to be completely variable to allow for the control 
of magnetic forces on a construct via distance. Precision is also paramount. Given the cubic ratio 
of magnetic force to distance, a small change in distance would result in a compounded effect on 
applied force. Exactly precise movements are required. 
Fixed electromagnetic manipulation represents an interesting potential control mechanism 
for the manipulation of ferromagnetic particles. By controlling current through a magnetic plate 
system, an electromagnetic field can be generated which can manipulate the magnetic particles in 
the construct without any moving parts. No moving parts means reduced vibration, wear and tear, 
and more compact overall design. Direct control of current through a plate is a relatively simple 
control mechanism and the geometries can be adapted to fit a variety of tissue types. 
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Electromagnets are powerful, however they require a large amount of power to achieve 
magnetic fields on the order of simple neodymium magnets. Passing large amounts of current 
generates heat, which can disrupt the environment inside an incubation chamber. Passing large 
currents through a plate is dangerous and considerations for safety would be paramount. Larger 
electromagnetic noise and disruption field may disrupt other control/measurement systems nearby. 
Electroplating/deposition becomes an issue, especially in a humid environment such as an 
incubator. 
Motor controlled manipulation of a neodymium magnet involves translation of a magnet 
via a physical motor driven system. By controlling the total distance of a magnet of a fixed strength 
from a magnetized tissue construct, we can control the magnetic forces on the tissue construct. The 
action of all described types of motor control would produce the same effect, which is to manipulate 
the motion of a magnet in space relative to a magnetized construct. Speed of translation, frequency 
of repetition and strength of the magnet are all variable parameters. This method should limit heat 
generation. Magnetic fields are cube of distance so modeling magnetic forces will be possible. 
Further, manipulation of a rare earth magnet is relatively safe. Electromagnetic noise and disruption 
is less of a concern with fixed strength magnets compared to electromagnetic systems, and 
electroplating/deposition is not an issue. 
There are design issues with a mechanical system. Moving parts introduces an element of 
wear and tear. Translation will introduce vibration, which could disrupt measurement systems and 
inhibit cell function. Compacting the design will be a key concern due to the necessity of inclusion 
of a motor and slide/translation system. Motors will need to be waterproof and corrosion resistant 
for use in an incubator. 
There are many types of motor systems capable of translating a permanent magnet. An air-
controlled system can be compact and strong with minimal vibration and high-speed translation. 
Air controlled systems require advanced control systems. The stroke distance of an actuator is 
limited and controlling traversing speed represents a non-trivial challenge. A hydraulic system can 
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be strong with minimal vibration and high-speed translation. Hydraulic controlled systems require 
advanced control systems. The stroke distance of an actuator is limited and controlling traversing 
speed represents a non-trivial challenge. Motor control of hydraulic fluids is non-trivial and 
requires significant design work. An electronic linear actuating system can be very strong and 
compact with minimal vibration. Controlling speed of translation is relatively easy and the control 
systems for electronic linear actuators don’t require air pressure generation or liquid reservoirs and 
pumps. Also, electronic linear actuators are fairly ubiquitous so obtaining parts would be easy. 
Electronic linear actuators are typically slow if their speed is variable. Also they have limited stroke 
distances and it can be difficult to program discrete distance control. Controlling exact distances of 
travel without the actuator extending or contracting a full stroke distance is very difficult and can 
result in a low degree of precision. Motor control is fairly easy and can be converted to linear 
motion using a variety of methods. With a ball screw and slide mechanism, stepper/servo motors 
are very precise. Translation can occur relatively rapidly using the ball screw and slide method. 
With a rigid chain/belt system, speed can be improved, however accuracy and vibration aspects 
suffer. Ball screw and slide methods are used for precision machining and suit our purposes very 
well. Servo/Stepper motors are even more ubiquitous than electronic linear actuators. There are 
thousands of control systems available and motors can be configured for almost any design 
consideration. There is no stroke limit on the ultimate positioning system and servo/stepper motors 
can be configured to translate an object to any distance. Systems can be bulkier than other options 
due to the size of the motors. They can also be noisy and generate some vibration. 
We concluded that based on design requirements and existing technologies a stepper motor 
driven ball-screw slide mechanism translating a fixed strength neodymium magnet is the ideal 
solution for a magnetic stretch bioreactor. Our proposed design solution is presented in Figure 22. 
As a part of this study, we fabricated and tested our design with m3D-AHM. 
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Figure 22: Design concept of magnetic stretch bioreactor 
 
5.3.3 Microcontroller and UI 
We chose the C2000 launchpad as the controller for our system. The C2000 LaunchPad 
Microcontroller (C) is ideally suited for developmental/evaluation purposes. It contains a C2000 
chipset with 60MHz, 64 kb Flash, 12KB RAM, 9 PWM, and 4 HR PWM, 1 Capture, 22 GPIOs, 
12-bit 4.6MSPS ADC with 13 ch., SCI/UART, SPI, I2C. An h-bridge configuration was used to 
amplify the GPIO signals (which output 3.3v control signals) to higher power signals capable of 
driving a magnetic stepper motor. The TI C2000 chipset was designed for real-time control 
purposes and is frequently used in motor control applications. The LaunchPad configuration allows 
for accessible transfer of commands and real-time control via a USB-UART connection. There 
remains untapped potential for incorporation of real-time readout and control feedback systems to 
the C unit. The C allows for connection of LCD displays, capacitive touch systems, distance 
feedback systems, temperature sensors and potentially pH sensors for more complex bioreactor 
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control and sample analysis. Force and EKG probes could also be incorporated, however C 
systems with more powerful processing units, which are designed to handle high rate analog inputs, 
would be preferable. C2000 LaunchPad Cs utilize analog-to-digital converters (ADCs) which 
quantize continuous signals into digital outputs. This inherently results in some small error and is 
not ideally suited for real-time analysis of complex analog waveforms. The MSP family of TI 
microcontrollers are better suited for such purposes, however more research on suitable C systems 
would undoubtedly reveal stronger applicants. The versatility and favorable cost of the C2000 C 
system, however makes it a suitable choice for our current endeavors. All control code was written 
in C. It was found that each stepper motor step accounted for 0.012654 mm of axial translation. A 
UI was developed in order to allow for direct control of the system through a graphical interface 
(Figure 23). 
 
Figure 23: Prototype of a magnetic stretch bioreactor, A, µC, B, Stage mount, C, User interface,  
                  D, Bioreactor system. 
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5.3.3 Magnetic forces and efficacy of Fe2O3 
 Fibrin samples prepared with varying concentrations of Fe2O3 became darker and slightly 
stiffer with increasing iron content (Figure 24A). Upon application of a magnetic field, axial 
displacement was observed. The patches remained intact and underwent smooth deformation under 
magnetic load. A force curve was calibrated in order to determine the active forces on samples of 
fibrin containing different amounts of iron. It was determined that increasing Fe2O3 loading led to 
a direct increase in the forces generated at a discrete distance. Further, controlling the maximum 
distance of the magnet from the leading edge of a patch allowed for a baseline force to be present 
(Figure 24C). Maximal deformation was assessed when the magnet was 10 mm from the leading 
edge. Higher iron content was observed to produce larger axial distortions at each discrete distance 
(Figure 24D). Maximal stretch with 3 and 7 wt% Fe2O3 loads were 5 and 10% stretch respectively.   
 
Figure 24:  Magnetic stretch forces, A, Fibrin gels with 8 different concentrations of Fe2O3, B,  
                    Magnetically induced deformation, C, Magnetic forces with changing  
                    concentrations, D, Deformation correlated with concentrations. 
 
5.3.4 Toxicity of Fe2O3 
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Effects of Fe2O3 content on AHM formation and function were assessed with regards to 
twitch force, appearance and immunohistological properties (Figure 25). At day 4 after formation, 
the control, 3 wt% and 7 wt% magnetic seeded patches exhibited the same contractile activity. At 
day 7 after formation, there was a significant drop in functional activity of iron containing heart 
muscle. There did not appear to be any difference in the severity of the force drop off from day 4 
to day 7 between groups containing 3 and 7 wt% iron oxide. Fe2O3 containing patches exhibited a 
reduced definition around the edges of the patches (Figure 25B, C and D) and significantly less 
well defined α-actinin expression when compared with control heart muscle (Figure 25E, F and G). 
Collagen expression appeared to be unaffected, however no numerical assessments were applied. 
 
Figure 25: Toxicity effects of Iron Oxide (Fe2O3), A, Effects of Fe2O3 on twitch force, B, C, D,  
                   Images of 0, 3 and 7 wt% heart tissue patches, E, F, G, IHC probing for DAPI (blue), α- 
                   actinin (green) and collagen (red) for each respective concentration. 
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5.3.5 Magnetic forces, loading and toxicity of Fe3O4 
The magnetic properties of the as-bought α-Fe2O3 and our synthesized Fe3O4 MNPs were 
investigated using a vibrating sample magnetometer (VSM) at 300K. For 100 nm and 300 nm 
MNPs, the saturation magnetization (Ms) values are 79 and 82 emu/g and coercivity values are 43 
and 37 Oe respectively. The bulk α-Fe2O3 used for the preliminary experiments has an Ms of ~5 
emu/g. Loading with Fe3O4 produced a 10 fold increase in sensitivity to magnetic fields. As such, 
we were able to achieve viable stretch activity (10-15% stretch) with less than 1 wt% Fe3O4. 
Toxicity effects of 1 wt% Fe3O4 loads were negligible. There was no visible reduction in definition 
around the edges of the patches when comparing loaded and unloaded controls. Fe3O4 particles 
were found to be homogenous in size and shape (Figure 26). Loading occurred well in the fibrin 
gel matrix, however some microscopic clumping was observed upon loading fibrin gel with Fe3O4 
under SEM. 
 
Figure 26: SEM of characterized Fe3O4 particles and fibrin gel. 
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5.4 Discussion 
 Typical mechanical stretch bioreactors inherently place stress on fragile scaffolds. In our 
experience with contact-based stretch bioreactor systems, prolonged stretch regimens primarily led 
to deformation and even tearing under the gentlest stretch cycles. Further, direct contact bioreactor 
systems necessitate some degree direct physical of interaction between the bioreactor system and 
the cultured tissue. Our heart muscle tissues are cultured in disposable vessels and nothing is re-
used. Re-using culture materials is generally considered bad practice as it can add a potential source 
for contamination. In best case scenarios for contact based systems, a custom chamber must be 
built for each culture cycle. Expediency often necessitates re-using these custom built chambers 
after a rigorous decontamination procedure, however such procedures are not full-proof and add 
complexity and uncertainty to an already difficult process. Many bioreactors use open air chambers 
in order to bypass these issues. In our experience, open air culture chambers are at a much higher 
risk for contamination. Non-contact stretch bioreactors should not need custom culture chambers. 
In our case, we did not have to modify the culture chambers in any way and were able to use 
rigorous sterile technique. 
 A traditional stretch bioreactor relies on physical attachment to the scaffold at several 
anchor points. The arm holding the edge of the scaffold is then translated axially in an oscillating 
pattern. This method provides a single degree of axial control, applies discrete points of stress, and 
relies on the scaffold to distribute forces along the axis of deformation. Physical distortion of a 
scaffold can cause deformation and break at the points of contact due to a lack of force distribution. 
Further, this mechanism of stretch has little physical resemblance to the forces involved in the heart 
under rhythmic contractile stretch. More advanced bioreactors which attempt to mimic 
physiological conditions apply a deformation force to a pliable surface underneath the culture dish. 
A piston-like component moves tangentially to the surface of a culture plane and pushes the pliable-
PDMS surface vertically. This distends the cultured tissue in a manner more closely related to the 
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mechanics of heart muscle in vivo. Unfortunately, discrete control can be more difficult under these 
circumstances. Further, such systems necessitate custom built chambers and exhibit little geometric 
control. We attempted to bypass these issues by developing a non-contact stretch bioreactor system 
which uses magnetic forces in order to induce the deformation forces. 
 In our preliminary studies, we used Fe2O3 as the ferromagnetic component of our scaffold. 
The powder which we purchased was fairly uncharacterized (<5 µm diameter) and was not in any 
way functionalized to make it less toxic. Adding higher weight percentages of Fe2O3 made the 
scaffolds stiffer and darker in color. After a certain load, Fe2O3 precipitated out of the scaffold. We 
found that 11 wt% was the highest load at which the fibrin gel could encapsulate the powder without 
protocol modification. Physical stretch regimens typically involve an axial deformation of 5-15%. 
We were able to achieve deformations in this range using loads upwards of 5 wt%. At 7 wt%, a 
deformation of 12% stretch was possible. Using uncharacterized iron (III) oxide, we were able to 
magnetize our scaffold and induce physiologically relevant levels of stretch without saturating the 
scaffold (Figure 24). 
Iron oxide is considered slightly toxic in the body, and as such we expected a negative 
effect when loading with unmodified iron powder. After 4 days of culture, there was no difference 
in activity between AHM formed using Fe2O3 loaded scaffolds and controls (Figure 25). After 7 
days of culture, there was a significant drop in contractile activity between AHM formed on both 
3wt% and 7wt% Fe2O3 fibrin scaffolds and controls. As such, a delayed toxic effect was observed. 
We confirmed a change in cellular expression with IHC microscopy. Controls exhibited higher 
levels of α-actinin and better overall organization than 3 and 7 wt % AHM constructs. 
Such effects were expected, however the above study was intended as a proof of concept 
for the base principles involved. In order to reduce toxicity and improve the versatility of the 
system, we set out to synthesize a new magnetic component for our scaffolds. In coordination with 
Dr. Randy Lee’s lab, we developed well characterized Fe3O4 nanoparticles (Figure 26). The 
particles exhibited a 10-fold increase in magnetic sensitivity over the Fe2O3 particles used 
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previously. Further the uniform structure of the particles allows for more uniform application of 
magnetic forces within the scaffold. We were able to achieve 15% axial stretch using only 1 wt% 
of the 300 nm Fe3O4 nanoparticle. At such levels, toxic effects were negligible at 7 days, however 
higher loads of particle produced negative effects within 8 days of culture. Toxicity can be reduced 
via functionalization of the nanoparticles. Common techniques involve silicating the surface of the 
nanoparticles or functionalizing the magnetic core with polymer chains. Should toxicity of the 
particles become a concern, Dr. Randy Lee’s group is very familiar with the necessary synthesis 
techniques to combat such issues. 
Constructs were stretched using magnetic fields and the highly characterized 300 nm Fe3O4 
nanoparticles. The stretch protocols were highly tunable via parameters sent to the user-interface. 
Starting distance, frequency (magnet speed), ending distance and ramp speed were all parameters 
which could be adjusted in order to develop the best stretch protocol.  
5.5 Summary 
We developed a novel, non-contact, stretch based bioreactor to induce mechanical 
stimulation of tissue engineered cardiac muscle. The system is capable of delivering axial stretch 
via application of an oscillating magnetic field to a magnetized AHM construct. We began with 
bulk, uncharacterized iron oxide as the magnetic component. We then synthesized highly magnetic, 
low toxicity Fe3O4 magnetic nanoparticles. The system is capable of delivering physiologically 
relevant stretch without issuing undue stress on the constructs. 
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